Managing fluid levels in a patient and associated devices, systems, and methods

ABSTRACT

Devices, systems, and methods for delivering fluid therapy to a patient are disclosed herein. An exemplary method can comprise obtaining a urine output rate from a patient; causing a diuretic to be provided to the patient at a dosage rate, wherein the dosage rate is increased over a period of time such that the urine output rate increases to be above a predetermined threshold within the period of time; and causing a hydration fluid to be provided to the patient at a hydration rate. The hydration rate can be set based on the urine output rate to drive net fluid loss from the patient.

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a continuation of U.S. patent applicationSer. No. 17/806,681, filed Jun. 13, 2022, which is a continuation ofU.S. Ser. No. 17/112,925, filed Dec. 4, 2020, now U.S. Pat. No.11,627,912, which claims priority to U.S. Provisional Application No.62/945,058, filed Dec. 6, 2019, the disclosures of which areincorporated herein by reference in their entireties.

TECHNICAL FIELD

The present disclosure relates to methods, devices, systems, andalgorithms for managing patient fluid levels and, in particularembodiments, treating fluid overload conditions for patients with heartfailure.

BACKGROUND

Physiological systems in humans seek to naturally maintain a balancebetween fluids ingested and fluids that are excreted. When there is animbalance of fluids, a patient may suffer from fluid overload in whichan excessive amount of fluid is retained. Patients may be in a fluidoverloaded condition due to acute decompensated heart failure (ADHF),chronic heart failure (CHF) or other conditions in which insufficientfluid is excreted to avoid fluid overload in the body. Patients in fluidoverload may suffer from shortness of breath (called dyspnea), edema,hypertension and other undesirable medical conditions that are symptomsof fluid overload.

To treat fluid overload, patients are typically treated with a diureticdrug which induces and/or increases urine production. Producing andexcreting urine reduces the amount of fluid and sodium in the body andthus may be used to treat a fluid overload condition. Diuretics can begiven orally as a pill or as an IV (intravenous) injection. IV diureticsare typically used when oral diuretics are no longer effective or ableto be absorbed. Where “diuretics” are mentioned, authors primarily referto IV diuretics. Popular loop diuretics are diuretics that act at theascending limb of the loop of Henle in the kidney. Examples of loopdiuretics include: Bumetanide (Bumex®), Ethacrynic acid (Edecrin®),Furosemide (Lasix®), Torsemide (Demadex®).

The short-term effects of diuretics on urine production are notadequately predictable to administer high doses at early stages oftreatment. For example, one patient may produce much less urine thanexpected for a given does of diuretic, while another patientadministered the same does may produce excessive amounts of urine. Thisraises concerns of hypotension (low blood pressure) and vital organdamage in the patient. As a result, it is difficult to predict whichpatients will respond to a certain dose of a diuretic by excreting noneor too small amounts of urine, and which patients will respond byexcreting excessive amounts of urine.

The potential for substantially different responses and treatmentoutcomes in response to the same dosage of diuretics createsuncertainties for physicians such that safe and correct diuretic dosingfor an individual patient requires monitoring the patient's clinicalsigns and symptoms over a period of time. Because of theseuncertainties, physicians may initially prescribe a conservative (low)diuretic dosage and wait a few hours before considering whether toincrease the dosage. The conservative low dose approach starts with alow diuretic dose, and slowly and incrementally increases the dosageuntil the patient's urine output reaches a threshold level, e.g., rate.Slowly increasing the diuretic dosage avoids causing an excessive urineoutput that can lead to hypovolemia and other undesirable medicalconditions.

The current standard practice for treating fluid overload in ADHF andCHF uses a conservative low-dose approach that can prolong the treatmenttime to relieve a fluid overload condition in a patient. Generally, aphysician increases a diuretic dosage at six to twelve hours intervals.These long intervals are often required to allow the patient to react toa new dosage level of a diuretic and produce urine at a rate induced bythe new level of a diuretic. At the end of each interval, the physiciandetermines if the diuretic dosage should be changed, such as increased,to cause the patient to produce a desired level of urine. Because theseintervals are typically several hours in length, it may take six hours,twelve hours, a day or more to determine a safe, efficacious dosagelevel of a diuretic. For example, in patients who have not taken priorloop diuretic therapy, an initial IV furosemide dose of 20 to 40 mg isreasonable. Max diuretic dose recommended by regulatory guidelines is 40to 80 mg of furosemide equivalent IV bolus. Subsequently, the dose canbe titrated up according to the urine output to a maximum intravenousdose of 80 to 100 mg of furosemide. In the patients that developed someresistance to diuretics, doses need to be higher.

One aspect of this conservative approach for reducing fluid overload isthat the patient's symptoms associated with fluid overload may beprolonged while the physician determines and administers a safe andeffective diuretic dosage to achieve a desired urine output rate. Onedrawback of this delay is that the clinical state underlying the fluidoverload condition may worsen due to the prolonged fluid overloadcondition. For example, delays of many hours or days can occur beforeurine output reaches the desired levels to cause significant fluid lossand relieve the patient's fluid overload condition. Another drawback isthat the patient is hospitalized for several days (e.g., 4-5 days),which is expensive. Additionally, even after receiving a conventionaltreatment for reducing fluid overload about 23% of the patients arereadmitted for fluid overload within 30 days. As a result, there is along-felt need to reduce the time needed to cause a patient to increaseurine output using a diuretic and more quickly cause the patient tooutput sufficient urine to reduce a fluid overloaded condition.

Another concern with using diuretics to treat fluid overload conditionsresults when the urine flow of a patient reaches high flow rates.Although high urine flow rates are beneficial in quickly reducing afluid overload condition, high urine flow rates risk excessivelyreducing the volume of blood in the vasculature, as well as increasedexcretion of electrolytes. Rapid removal of electrolytes may lead toelectrolyte imbalance (e.g. loss of potassium), which can furtherdeteriorate a patient's clinical condition. These risks and side effectsof IV diuretics, which are often referred to as hypovolemia andhypokalemia, are known unnecessary risks and an unmet clinical needstill is present during this necessary and commonly used therapy.

Excessive urine flow, such as in excess of 2.5 liters per day, may leadto hypovolemia, hypokalemia and other undesirable medical conditions.The risks of excessive urine flow caused by conventional fluid overloadtreatments, such as by using diuretics, are traditionally mitigated bylimiting the rates at which urine flow is induced. Limiting the urineflow rates tends to increase the period needed to reduce a fluidoverload condition in a patient.

To avoid these drawbacks, the approved dosages for certain diureticshave been limited, at least in part, to avoid or reduce the risks ofhypovolemia, hypokalemia and other such undesirable medical conditionsassociated with intravascular blood volume becoming too low. Forexample, in a patient previously unexposed to loop diuretics (diureticnaïve) the furosemide diuretic is recommended to be administeredintravenously (IV) at an initial dose of 20 milligrams per hour (mg/hr),and may be increased only every 6 to 12 hours. In heart failure patientsthat routinely take oral diuretics initial doses and stepwise doseincreases need to be adjusted by a significant amount and this furthercomplicates the titration of therapy.

In conventional approaches, the dosage level is not to be increased oncea certain urine output level is reached. Other commonly prescribeddiuretics, such as loop diuretics, such as bumetanide and torsemide;thiazide diuretics, such as hydrochlorothiazide and metolazone;potassium sparing diuretics, such as spironolactone; and carbonicanhydrase inhibitors, such as acetazolamide, are believed to also haveregulated dosage limits to prevent excessive urine flow rates and otherpossible side effects of these drugs.

SUMMARY

A primary purpose of hospital admissions in heart failure patients is toremove extra fluid. However, for more than half of the heart failurepatients during a hospital admission in the United States, the totalfluid loss is less than five pounds (2.3 kilograms), which generallydoes not achieve effective relief from a fluid overload condition.Accordingly, there remains a need to improve upon conventional fluidmanagement technologies, and achieve greater net fluid losses frompatients in a shorter timeframe.

Embodiments of the present technology address the need for improvedadvances in patient fluid management, e.g., by creating an at leastpartially automated system that enables safe administration ofdiuretics, increased diuretic efficiency, and at least moderatesdiuretic resistance, while conserving valuable hospital resources andpatient comfort. As described herein, clinical tests of embodiments ofthe present technology have caused rapid decongestion, removed excessfluid, increased sodium excretion, and reduced weight, each withimproved effectiveness and/or speed. For example, whereas conventionalsystems and methods for treating fluid overload required hospitalizationexceeding multiple days (e.g., 4-5 days), embodiments of the presenttechnology are able to diagnose and/or relieve fluid overload conditionswithin 1-2 days.

The present technology relates to methods, devices, systems, andalgorithms to reduce fluid levels in a fluid overloaded patient, such asone suffering from ADHF, CHF or other conditions that result in fluidoverload. In some embodiments, an exemplary method includes a diuretictreatment regimen having multiple phases, including a Phase I, II, andIII. Phase I can include determining an appropriate diuretic dosage thatis specific to the patient, which may be done in iterations. Forexample, in some embodiments during a first iteration of Phase I, aninitial diuretic dose, possibly automatically, is delivered to thepatient. The dose is increased during Phase I, such as incrementally insteps, progressively increasing steps and/or exponentially. For example,the dose may be increased in a stepwise manner every two to threeminutes. The dose can be increased until the patient reaches a desiredurine output level or rate and/or until an upper threshold is reached.The first diuretic dosage provided to the patient is at the start oftreatment and subsequent dosages can be in response to urine outputfalling below a threshold and/or outside a threshold range. Thethreshold may define a maximum (e.g., total) amount of the diureticgiven to the patient, a maximum rate at which the diuretic is given tothe patient, or a maximum period for Phase I, such as one hour.

Phase II is optional and can allow the patient to respond to thediuretic dose given during Phase I. After the urine output reaches adesired level during Phase I, Phase II can include delivering thediuretic to the patient at a constant maintenance dosage level for anextended period (e.g., at least one hour, at least two hours, fourhours, 8 hours, 12 hours, 24 hours, or 36 hours). The maintenance dosagelevel is calculated based on the diuretic dosage in Phase I whichresulted in urine output exceeding the desired output level.

Phase III is optional and can run concurrently with Phase II. DuringPhase III, diuretic continues to be administered and net fluid levels ina patient (e.g., a patient who has responded to Phase I and is producingabove a threshold level of urine) can be rapidly reduced by infusing ahydration fluid or solution (e.g., saline) into the patient. DuringPhase III, the hydration fluid infused into the patient can be (i)automatically adjusted to match urine output during relatively low urinerates, (ii) automatically adjusted to reduce the hydration fluid to lessthan urine output (e.g., at least 10%, 20%, 30%, 40%, or 50% of urineoutput) during a range of higher urine rates, and/or (iii) automaticallyadjusted to maintain a substantially constant hydration fluid rate(e.g., within 10% to 20% of a maximum hydration fluid rate), while theurine output exceeds an upper urine threshold. During Phase III, themaintenance dosage of the diuretic may be adjusted, e.g., by restartingPhase I and initiating a re-ramp of the diuretic (e.g., in anexponential manner). Phase I can be restarted either by resuming wherePhase I was last stopped or by repeating Phase I from its initialstarting point.

Simultaneous with the diuretic regimen described above, the amount orrate of hydration solution given to the patient may be related to theamount or rate of urine output. For example, the amount or rate of thehydration solution delivered to the patient may be less than the amountor rate of urine output at higher levels of urine output. The rate ofhydration infusion may be adjusted to match the rate of urine output fora particular period of time (e.g., the first hour of therapy) and/or athreshold volume amount (e.g., until at least 250 milliliters (ml) ofurine has been produced). The rate of hydration solution infusion mayremain at a constant rate while the urine rate exceeds a threshold highurine rate.

The maintenance diuretic dosage for Phases II and III may be calculatedbased on a percentage, such as in a range of 100% to 10% percent (e.g.,20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, etc.), of a maximum dose of thediuretic given during Phase I. The percentage reduction of the maximumcontinuous maintenance dose may be a ratio of the diuretic dosage(amount or rate) reached during Phase I that resulted in the urineoutput exceeding the desired output level and the maximum diureticamount or rate of the upper threshold in Phase I.

If the upper threshold (e.g., the total amount of diuretic delivered tothe patient) is reached in Phase I before urine output reaches thedesired output, the patient may be diagnosed as diuretic resistant, anda different diuretic or a different treatment may be given to thepatient. Such treatments can include ultrafiltration and/or use of anartificial pump (e.g., a venous pump) to enable the kidneys to producemore urine. If the urine output falls below a lower urine threshold fora certain period in Phase III, the regimen may repeat Phase I to inducegreater urine output and identify a more effective diuretic dose level(e.g., a higher diuretic dosage).

Phase I may be restarted if the urine output (e.g., rate or amount)falls below a urine output threshold during Phase I, II or III. WhenPhase I is resumed from where it last stopped, it can be restarted atthe rate of diuretic dosage which was given at the end of the prioriteration of Phase I. At the end of each iteration of Phase I, themaintenance diuretic dosage may be calculated based on the total amountof diuretic given during all of the iterations of Phase I.

Phases I and III may be applied as independent treatments. For example,an operator (e.g., a physician, health care specialist, nurse, etc.) maydetermine an initial diuretic dosage in a conventional manner andthereafter treat a patient using the Phase III portion of the regime.Similarly, an operator may use the Phase I portion of the regime toquickly determine an effective diuretic dosage to achieve a desiredurine output rate and thereafter choose not to adjust the maintenancedosage of the diuretic or not to infuse the hydration fluid into thepatient or select a different relationship between the diuretic dosage,urine output and hydration fluid solution infusion than is proposed inPhase III. Further, since Phase II is optional, Phase III may startimmediately after Phase I.

The present technology may include a method to treat patients sufferingfluid overload and can comprise: administrating a diuretic, such asautomatically, to the patient to increase urine output of the patient;determining urine output by the patient during the administration of thediuretic; infusing a hydration fluid into the patient; and automaticallyadjusting a rate of the hydration fluid infused into the patient toachieve a desired net fluid loss in the patient. In some embodiments,the method may include automatic adjustment of the rate of the hydrationfluid based on a difference between the urine output and the desired netfluid loss. The automatic adjustment of the rate of the hydration fluidmay be calculated based on a current rate increase of the urine output,such that the rate increase of the hydration fluid is reduced inresponse to the urine output exceeding a first threshold output, such asa current rate of urine output. Additionally or alternatively, theautomatic adjustment of the rate of the hydration fluid may includeincreasing the rate of the hydration fluid to a rate within 10% of acurrent rate of urine output, until the current rate of urine outputreaches a first threshold output. The first threshold output may be aurine output rate in a range of 200 ml/hr to 240 ml/hr or an equivalentvolume of urine output. The rate of the hydration fluid infusion may belimited to a maximum limit for the hydration fluid while a current urineoutput rate is above a second threshold is above 500 ml/hr, above 700ml/hr, or above 1020 ml/hr.

In some embodiments, the method may include limiting a rate of thehydration fluid infusion to a maximum limit for the hydration fluid;maintaining the rate of the hydration fluid infusion at the maximumlimit while the urine output exceeds a maximum threshold urine outputrate; ending the treatment when the net fluid loss reaches a desiredamount for the net fluid loss; automatically adjusting the diureticadministered to the patient based on the urine output; increasing a rateof the diuretic being administered until the urine output reaches adesired minimum urine value, wherein the minimum urine value is aminimum urine output rate; and/or automatically adjusting the diureticby increasing the diuretic level at intervals of five minutes or less,e.g. two to three minutes, until the urine output reaches the desiredminimum urine value. In some embodiments, each increase in the diureticlevel, e.g., during a diuretic dosage determining phase or ramp, may bea greater increase than the immediately prior increase.

In some embodiments, the method may include determining a reduceddiuretic dosage rate in response to the urine output reaching thedesired minimum urine volume or rate. The reduced diuretic dosage rateis below the diuretic dosage rate when the urine output reached thedesired minimum urine value or rate. The diuretic may be administered atthe reduced rate for a period of at least one hour such as periods oftwo, three or four hours. This reduced diuretic administration rate mayinvolve reducing the diuretic infusion rate to a very low rate until themeasured urine rate drops below a desired threshold or a period, such asone hour, elapses. The diuretic administration rate may then becalculated based on the time required for the urine rate to drop to thedesired threshold, or reduced by a predetermined percentage (such as25%) if the urine output remains above the threshold when the period ofvery low infusion completes.

In some embodiments, a method of treatment or an automated regimen formanaging or optimizing net fluid volume removal and/or enhancing qualityof urine removed includes an initial personalized diuretic dosagedetermining phase followed by a fluid reduction phase. During theprocess of determining the diuretic dosage determining phase, thepatient's urine response to an administered diuretic at increasinglevels is assessed within a predetermined period of time to establish adiuretic dosage to be used in the following phase and/or to assess ifthe patient is diuretic resistant. During the fluid reduction phase, thediuretic is infused at the established diuretic dosage while replacing aportion of the urine production with hydration fluid, e.g., to maintainintravascular volume and/or turn off salt and water retaining mechanismsto optimize net volume removal. Throughout the fluid therapy, urineoutput is continuously monitored. The diuretic dosage may be adjustedbased on the urine output rate. For example, very low urine output(e.g., less than 25 ml/hr averaged over the previous 15 minutes) mayindicate equipment malfunction or improper set up and an alert may begiven to the user. As another example, low urine output (e.g., low urineoutput may be defined as less than 325 ml/hr averaged over the previous3 hours, or be defined by an integral debt function where the debt ismore than 150 ml over the previous 3 hours) may indicate that a greaterdiuretic dosage may be allowed and a diuretic dosage may bereestablished. For example, the user may select to reenter the diureticdosage determining phase or manually increase the dosage. As anotherexample, high urine output (e.g., more than 625 ml/hr averaged over theprevious 3 hours) may indicate too much diuretic is being infused andthe infused diuretic may be reduced for a period of time (e.g., reducedto 0 to 0.4 ml/hr for 50 minutes or until the urine output has droppedbelow 525 ml/hr) and a new diuretic dosage may be established. Forexample, the new dosage may be a fraction of the previous dosage basedon how quickly the urine output decreased during said period of time orbe established by reentering the dosage determining phase. Furthermore,hydration fluid may be infused throughout the fluid reduction phasebased on urine output.

The present technology may be embodied as a fluid management systemcomprising: a hydration fluid pump configured to pump a hydration fluidinto a patient; a diuretic pump configured to pump a diuretic into thepatient; a measurement device configured to measure urine output of thepatient; a computer executing an algorithm configured to: determine anamount or rate of urine output of the patient; automatically inject adiuretic to the patient by controlling the diuretic pump to deliver thediuretic at a dosage rate determined by the algorithm; automaticallyinfuse a hydration fluid into the patient by controlling the hydrationfluid pump; and automatically adjust the rate or the amount of thehydration fluid infused into the patient to achieve a desired level orrate of net fluid loss in the patient or net sodium loss.

The algorithm may be configured to determine the automatic adjustment ofthe rate of the hydration fluid based on a difference between the urineoutput and the desired net fluid change; limit a rate of the hydrationfluid infusion to a maximum limit for the hydration fluid; maintain therate of the hydration fluid infusion at the maximum limit while theurine output exceeds a maximum threshold urine output rate, and/or stopthe administration of the diuretic when the net fluid loss reaches adesired amount for the net fluid loss. Additionally or alternatively,the computer algorithm may be configured to automatically adjust thediuretic administered to the patient based on the urine output. Theautomatic adjustment of the diuretic may include increasing a rate ofthe diuretic being administered until the urine output reaches a desiredminimum urine value, such as a minimum urine output rate. The adjustmentof the diuretic may include automatically increasing the diuretic levelat intervals of five minutes or less until the urine output reaches thedesired minimum urine value, wherein at least one of the increases inthe diuretic level is a greater increase than the immediately priorincrease. Each of the increases in the diuretic level is greater thanthe increase of the immediately prior increase. The automatic adjustmentof the diuretic may include: calculating a reduced rate for diureticadministration in response to the urine output reaching the desiredminimum urine value or rate, wherein the reduced rate is below and basedon a value of the diuretic administered when the urine output reachedthe desired minimum urine value or rate, and administering the diureticat the reduced rate for a period of at least one hour.

BRIEF DESCRIPTION OF THE DRAWINGS

Features, aspects, and advantages of the presently disclosed technologymay be better understood with regard to the following drawings.

FIG. 1 is a schematic view of a patient hydration system configured tomonitor urine output and control the injection of a fluid into apatient, in accordance with embodiments of the present technology.

FIG. 2A is a graphical representation showing a timeline of diureticdosage dispensed by a fluid management system during a treatmentregimen, in accordance with embodiments of the present technology.

FIG. 2B is a graphical representation showing a timeline of urine flowrate achieved by the diuretic dispensed by the fluid management systemduring the treatment regimen of FIG. 2A.

FIG. 3 is a graphical representation showing a relationship betweenurine output, hydration fluid infusion, and net fluid loss, inaccordance with embodiments of the present technology.

FIG. 4A is a flowchart for controlling diuretic dosage during a diureticdosage determining phase, in accordance with embodiments of the presenttechnology.

FIG. 4B is a graphical representation showing a relationship betweendiuretic dosage rate and total diuretic delivered, in accordance withembodiments of the present technology.

FIG. 5 is a flowchart of a continuous infusion or fluid reduction phase,in accordance with embodiments of the present technology.

FIG. 6 is a graphical representation of diuretic dosage rate andcorresponding urine output rate, in accordance with embodiments of thepresent technology.

FIG. 7 is a flowchart illustrating down-titration or decrease of adiuretic dosage rate, in accordance with embodiments of the presenttechnology.

FIG. 8 is a graphical representation of down-titrating or decreasing adiuretic dosage rate, in accordance with embodiments of the presenttechnology.

FIG. 9 is a graphical representation of the relationship between urineoutput rate, hydration fluid infusion rate, and net fluid balance, inaccordance with embodiments of the present technology.

FIGS. 10 and 11 are flow diagrams of methods for causing net fluid lossfrom a patient, in accordance with embodiments of the presenttechnology.

A person skilled in the relevant art will understand that the featuresshown in the drawings are for purposes of illustrations, and variations,including different and/or additional features and arrangements thereof,are possible.

DETAILED DESCRIPTION I. Overview of Devices, Systems and AssociatedMethods for Managing Fluid Levels

Disclosed herein are devices, systems, and associated methods related tomanaging fluid levels of a patient. Relative to current fluid managementsystems, embodiments of the present technology can improve efficacy,safety and quality of fluid management treatment, improve resourcemanagement in a hospital, quickly assess if a patient is diureticresistant, and/or increase diuretic efficiency. Diuretic efficiency canbe defined as the amount of urine and/or excreted sodium obtained over agiven time per milligram of diuretic infused intravenously. One expectedresult of the present technology is that diuretic efficiency can beincreased by intravenous infusion of hydration fluid that containssodium and/or chloride. This is counterintuitive since a goal of fluidtherapy is net removal of salt (e.g., sodium and chloride) and fluid. Asdescribed herein, embodiments of the present technology can increase netremoval of fluid and sodium while both the hydration rate and the urineexcretion or output rate are also increased, and, in some embodiments,with the urine excretion rate being increased more than the hydrationinfusion rate. Increasing diuretic efficiency, which embodiments of thepresent technology do, as opposed to increasing diuretic dose, is aclinically relevant and beneficial therapy, as it allows for thetreatment of fluid overload conditions in a more efficient manner (e.g.,shorter timeframe, higher net fluid loss, and/or higher net sodiumloss). Additionally, embodiments of the present technology areconfigured to increase diuretic efficiency while preventing hypotension,e.g., by automatically maintaining net fluid loss above a set fluid losslimit (e.g., at least 50 ml/hour, 100 ml/hour, 150 ml/hour, or 200ml/hour). As explained elsewhere herein, net fluid loss can becontrolled by adjusting the diuretic dosage rate, and/or adjusting thehydration infusion rate relative to the urine output rate, or morespecifically, based on whether the urine output rate is above or below anumber of different thresholds.

FIG. 1 shows a patient fluid management system 10 that includes a urinecollection and monitoring system 12 (“urine system 12”) and an automateddiuretic infusion system 14 (“diuretic system 14”). In some embodiments,the fluid management system 10 can further include an automatedhydration fluid infusion system 16 (“hydration system 16”). The urinesystem 12, diuretic system 14, and hydration system 16 can be connectedto a patient P by tubing lines (e.g., intravenous (IV) lines) 15, 23 forthe respective diuretic and hydration systems 14, 16, and a catheterline 32 (e.g., a Foley catheter, Texan Condom catheter, PureWickcatheter, etc.) for the urine system 12. The fluid management system 10can include a console 18 housing one or more pumps or electric motoractuators 22, 26, a computer (e.g., a controller or microprocessor(s))19, and a user input device 40 (e.g., a key pad) and output device 42(e.g., a display) in communication with the urine system 12, diureticsystem 14, and/or hydration system 16. The controller includeselectronic programmable memory and receives input from various sensors(e.g. a urine monitor, a hydration monitor, weight scales, flowmeters,optical sensors, fluid level meters, ultrasound fluid meters, feedbacksensors of pump speeds or actuator movements, pressure sensors, bloodpressure sensors, air detectors, etc.), and/or a user interface. Thecontroller is configured to automatically control actuators to infusethe hydration fluid and the diuretic, e.g., to promote safe andeffective diuresis of the patient.

The diuretic system 14 includes or is in fluid communication with asource of a diuretic 20. The diuretic 20 can include Bumetanide(Bumex®), Ethacrynic acid (Edecrin®), Furosemide (Lasix®), Torsemide(Demadex®), and/or other diuretics known in the art, each of which maybe part of a fluid solution (e.g., a mixture of saline and a diuretic orother agent). The diuretic 20 can be infused into the patient using aseparate IV tube inserted into a suitable peripheral vein of the patientor added to the hydration fluid prior to the infusion.

In some embodiments, the diuretic 20 may be contained in a syringebarrel (not shown) or other container (e.g., bag), and injectedintravenously through an IV needle. The diuretic system 14 may includemultiple syringes or containers of the diuretic 20 that are eachavailable for use, such that if a first syringe or container is spent,supply of the diuretic 20 can continue (e.g., without substantialinterruption) via a second (or third) syringe or container. As anexample, the diuretic system 14 can be designed such that twoindependent syringe pumps are available for use, each fluidly coupled toits own syringe filled with diuretic 20. It is noted that such syringesmay only be filled by pharmacists or other health care professionals,and thus may not be readily replaced (e.g., in less than a few hours).When the diuretic system 14 detects that the first syringe is empty,diuretic supply can begin (e.g., automatically or manually begin) todispense diuretic 20 from the second syringe. In some embodiments, thismay entail stopping a first syringe pump fluidly coupled to the nowspent first syringe, and starting a second syringe pump fluidly coupledto the second syringe. Additionally or alternatively, if only a singlepump is utilized, switching between the first syringe and second syringemay involve manipulating one or more valves such that the pump issupplied from the second syringe. Upon manually or automaticallyswitching to the second syringe, an alert to the operator can then bemade to let the operator know that the first syringe must be replacedwith a new full syringe.

Additionally or alternatively, the diuretic system 14 can predict whenthe diuretic 20 is nearly empty (e.g., will be empty in an hour), alertthe user, and/or automatically switch to the second syringe or ask theuser to confirm switching manually to the second syringe. In someembodiments, manually switching may be required for regulatory concerns,e.g., to ensure the diuretic system 14 does not automatically infuse alarge volume of diuretic 20 without user confirmation. Additionally oralternately, the system can be designed with only one syringe pump, andthe system can alert the operator in advance of the first syringe beingempty, and the operation can momentarily halt the syringe pump so thatthe first nearly empty syringe can be removed and replaced with a secondfull syringe, and the pump restarted to continue dispensing of diuretic.

By having a second (or third, fourth, etc.) syringe, or more generally abackup supply, administering the diuretic 20 can proceed withoutinterruption throughout a fluid therapy session. As described elsewhereherein, the lack of interruption can help ensure that the fluid therapy,described with reference to embodiments of the present disclosure, ismost effective and inhibits or prevents unnecessary delays. Morespecifically, interruption in therapy, even if for short periods, cancause urine output rate to drop and/or require a diuretic ramp (asexplained elsewhere herein) to be reimplemented. Embodiments of thepresent technology that utilize a backup supply of the diuretic 20, aswell as other redundancy measures explained herein (e.g., with respectto the hydration fluid source, urine collection, etc.) can thus avoidsuch interruption and enable more effective therapy.

The pump 22 can be a peristaltic pump, a syringe pump, a metering pumpor another device suitable for controllable injection of IV medication.In such embodiments including a syringe pump, the pump 22 can include amechanical injector operably coupled to the computer 19, such that thecomputer 19 causes movement of the injector to transfer the diuretic 20from the source to the patient. An actuator can be a mechanical actuatorunder an electric motor control by a rotary motor or a linear motor or aseries of electrically actuated solenoids configured to propel liquidthrough an IV delivery tubing toward the patient. The pump 22 oractuator delivers the diuretic 20 at a controlled continuous rate and/orin controlled boluses delivered at regular intervals through the IV line23 and into the patient. The pump 22 or actuator is controlled by thecomputer 19, which may have executable instructions or a softwarealgorithm incorporated in the console. The computer 19 or associatedalgorithm is configured to determine a pumping rate of the diuretic 20and/or associated solution to achieve a desired dosage for the diuretic20. The computer 19 controls the pump 22 or actuator to deliver dosageamounts of the diuretic 20 based on a treatment regimen prescribed,e.g., by an operator and managed by the computer 19. The control logicof the computer 19 can be a software or a firmware embedded therein tocontrol the infusion of diuretic based on the program time profile, userinput and/or input from various sensors.

The diuretic system 14 can include a reusable motor, actuator andcontrol electronics, as well as one or more reusable or disposable partsconnectable to the motor, actuator and electronics. The reusable ordisposable parts can include a medical agent (e.g., a medicament ordiuretic) container or reservoir (e.g., a plastic syringe, plastic bag,etc.), IV tubing set and needle. In some embodiments, the reusable anddisposable parts described herein are attached with attachment schemesthat are comparatively simple to engage and disengage, for example, in asingle-step procedure (e.g., snap connections).

In some embodiments, the diuretic system 14 can include one or moresyringe pumps. Each of the syringe pumps can be designed to allowattachment of needles, tubing, and other attachments to the syringepump, and can include a plunger mounted to a shaft that pushes a liquidout of a reservoir. The reservoir may be a tube-shaped structure havinga port at one end such that the plunger can push (i.e., discharge) theliquid out of the syringe pump. Syringe pumps can be coupled to anactuator that mechanically drives the plunger to control the delivery ofliquid to the patient. The linear actuator may comprise, for example, anut for rotating a lead screw to drive a plunger through the medicalagent reservoir. A syringe pump can be equipped with a plunger positionsensor, air bubble detector and other embedded electronics needed toprovide feedback signals to the controller. In some embodiments, thesyringe pump for administering an agent to a patient comprises ahousing, a lead screw, and a sliding block assembly. The sliding blockassembly can comprise a threaded portion capable of engaging anddisengaging from the lead screw, and a latching mechanism for quickengaging and disengaging of the syringe thus enabling quick change of anempty syringe for a full one. In some embodiments, a syringe pump foradministering diuretic to a patient comprises a housing. Within thehousing may be a motor, a gearbox operatively connected to the motor, ameans for sensing rotation of said motor (e.g., a tachometer or anoptical encoder), a controller (e.g., a microcontroller) acting tocontrol operation of said motor and monitor the quantity of diureticdelivered to the patient, and a pump assembly. In some cases, theplunger includes a fluid-contacting surface made from an elasticmaterial such as silicone rubber or urethane. In some cases, thereusable part forms a void space for receiving the lead screw when thelead screw is retracted from the reservoir.

In some embodiments, a combination of two or more medical agents may beneeded for optimal and/or effective diuresis of the patient. For thispurpose, in some embodiments, the disposable part can further include asecond reservoir for containing additional fluid agent, a second plungerfor driving additional fluid agent out of the second reservoir, a secondlead screw attached to the second plunger, and a second nut operable todisplace the second lead screw, such that when the reusable part and thedisposable part are attached, the second nut is coupled with the drivecomponent. In some embodiments, the step of controlling the device suchthat the fluid agent is delivered includes simultaneously driving bothof the first and second plungers (e.g., at the same rate or at differentrates). In other instances, the step of controlling the device such thatthe fluid agent is delivered includes independently driving the firstand second plungers (e.g., sequentially and/or intermittently).

In some embodiments, the pump may be a syringe pump or peristaltic pump.Although design of these two types of pumps is mechanically deferent,both can be considered computer-controlled, electrically actuatedmechanical devices for precise and controlled propulsion of liquid(i.e., solution containing diuretic of choice or a combination ofdiuretics, electrolytes and other active and passive ingredients) toinject the liquid solution into the patient's bloodstream through asuitable vein.

In embodiments including a peristaltic pump, a liquid solutioncontaining a diuretic may be supplied in the disposable container, whichcan be a plastic bag with attachments to plastic tubing, and thereusable part can be a peristaltic pump capable of engaging the plastictubing and propelling fluid from the bag into the patient under precisecontrol from the electronic controller. In such embodiments, thereusable component may incorporate an electric motor activated actuatorthat can be a roller pump with compression rollers cyclically engagingthe tubing or a liner peristaltic pump sequentially engaging,compressing and releasing the tubing, thus propelling the bolus of fluidforward towards the patient.

As shown in FIG. 1 , the diuretic 20 may be stored in a container (e.g.,bag). The container may include a solution (e.g., saline) with a certainconcentration of a diuretic. The concentration of the diuretic can beinput into the computer 19, such as via the user input device 40, whichmay include a scanner to read bar codes on such containers and therebyindicate the type of diuretic and concentration. Alternatively, acoupling between the container and the console 18 may be configured suchthat the coupling only receives a certain container that is known by thecomputer 19 to store a known diuretic at a certain concentration.

In some embodiments, The hydration system 16 includes or is connectableto a fluid source 24, such as a saline bag containing a saline solution(which may or may not be the same saline solution previously describedthat is mixed with the diuretic), a hydration fluid infusion pump 26(e.g., a peristaltic pump) optionally mounted to the console 18 that mayaccept an IV line 15. The IV line 15 is coupled or connectable to thefluid source 24 and an intravenous (I.V.) needle 28 for insertion into avein of the patient. The amount or rate of hydration fluid(s) flowingfrom the source 24 into the patient may be measured by a flow,volumetric, or other sensor downstream of the pump 26, or by the pumpingrate or number of rotations of the infusion pump 26. The amount or ratecan be an input, e.g., into the algorithm or computer 19. As explainedelsewhere herein, the pumping rate of the hydration fluid may beregulated by the computer 19 or associated algorithm and based, at leastin part, on the urine output and an electronically stored relationshipbetween urine output and infusion of the hydration fluid. The computer19 may monitor the amount of or change in hydration fluid in the source24, e.g., with input from a weight scale 38 weighing the source 24. Theamount of hydration fluid or rate of change of hydration fluid can alsobe measured by other means, such as a fluid level monitor, floatsensors, optical sensors, drip counters, flow measurement sensors, orthe like.

In some embodiments, the hydration system 16 can include multiple (e.g.,redundant) fluid sources 24, e.g., to ensure supply of the hydrationfluid can continue without interruption for the entirety of a therapysession. As an example of such embodiments, when the system or computer19 detects that the first source container is empty or near empty (e.g.,through measuring container weight, a reduction in flow rate, etc.),flow can be stopped from the first source and started from the secondsource. For example, supply may be switched from the first source to thesecond source by closing a first valve (e.g., a pinch valve applied tothe exterior of the fluid supply tubing), and opening a second valveallowing flow from the second container. An alert to the operator maythen be made to let the operator know that the first source containermust be replaced with a new full container. Additionally oralternatively, the hydration system 16 can predict when the fluid sourceis nearly empty (e.g., will be empty in 15 minutes), alert the user,and/or automatically switch to the second fluid source. In someembodiments, manually switching may be required for regulatory concerns,e.g., to ensure the hydration system 14 does not automatically infusehydration fluid without user confirmation. By having a second (or third,fourth, etc.) supply of hydration fluid, or more generally a backupsupply, infusing the hydration fluid can proceed without interruptionthroughout a fluid therapy session. As described elsewhere herein, thelack of interruption can help ensure that the fluid therapy is mosteffective, e.g., by relieving a fluid overload condition as fast and assafe as possible. Stated differently, interruption in fluid therapy,even if for short periods, can cause urine output rate to drop and/orrequire a diuretic ramp (as explained elsewhere herein) to bereimplemented. Embodiments of the present technology that utilize abackup supply of the diuretic 20, as well as other redundancy measuresexplained herein (e.g., with respect to the diuretic, urine collection,etc.) can avoid such interruption and thus enable more effectivetherapy.

The urine system 12 includes or is connectable to a disposable catheter30 (e.g., a Foley catheter) for placement in the bladder of patient, anddisposable tubing 32 that connects the catheter 30 to a urine collectiondevice (e.g., a disposable bag) 34. The amount of urine collected in thebag 34 can be monitored by a weight scale 36 or other urine flowmeasurement device which communicates with the computer 19. For example,the amount or rate of urine flow can be determined via a urinemeasurement device, fluid level monitor, float sensors, optical sensors,drip counters, flow measurement sensors, or the like. The amount or rateof urine collected can be monitored in real time by the computer 19 orcalculated. Similarly, the amount of fluid or diuretic 20 may bemeasured for example by a weight scale 38 and monitored by the computer19. Alternatively, the weight scales 36, 38 may be a single weight scalewhich measures the combined change in urine output and fluid input byand to the patient. The combined change in urine output and fluid inputindicates the net fluid change by the patient.

In some embodiments, the urine system 12 can include multiple (e.g.,redundant) independent urine collection devices 34, e.g., to ensurefluid therapy does not need to be stopped or interrupted due to a fullurine collection device. As an example of such embodiments, when thesystem or computer 19 detects that a first urine collection device isfull (e.g., by sensing the weight of the collection device, bycalculating the total collected volume with a flow sensor, etc.), urineflow from the patient can be redirected to the second collection device.An alert to the operator can then be made to instruct the operator toempty the first urine collection device and indicate its replacement inthe system. In some embodiments, the urine drain tubing leading from thepatient may be connected (e.g., through a “Y” fitting) to two flexibletubing lines each leading to one of the available urine collectiondevices. Flow to each collection device may be controlled with pinchvalves that compress the tubing from the outside, thereby allowing flowthrough the tubing to be stopped when the pinch valve is released. Ifthe first pinch valve is opened and the second one is closed, urine flowwill be directed to the first collection device and not the secondcollection device. When the first collection device is detected by thecomputer 19 to be full, the first pinch valve can close and the secondpinch valve can open, thus switching urine flow to the second collectiondevice and allowing the first collection to be taken offline andremoved.

In some embodiments, the fluid management system 10 corresponds or issimilar to the Reprieve Cardiovascular™ system, developed and clinicallytested by Reprieve Cardiovascular, Inc. of Milford, Mass.

The computer 19 may include a processor(s) and tangible, non-transientmemory configured to store program instructions, settings for thepatient fluid management system 10 and data collected or calculated bythe computer 19. The data may include historical data for the patient,e.g., diuretic doses delivered to the patient, urine output volume orrate, amount of hydration fluid infused into the patient, the weight orchange in weight of the patient at various times during the infusion ofthe diuretic, indicators of the patients renal function (e.g., estimatedglomerular Filtration Rate (eGFR)), and/or the time(s) during which thepatient was treated with the patient fluid management system 10.

As previously described, the console 18 and/or the computer 19 may havea user input device 40, such as a key pad, and a user output device 42,such as a computer display. A user may interface with the computer 19through the input device 40, which may be used to input certainparameters of the treatment sessions, such as a desired fluid balancelevel, desired urine output level, the planned duration of the inputbalance level or urine output level, the diuretic type, and minimum andmaximum dosages of the diuretic. Other inputs may be regarding thepatient (e.g., sex, weight, “dry” weight, age, target fluid removalvolume, renal function, etc.). The inputs may be used by the computer 19to lookup from tables or other data stored in the computer 19 certainparameters such as maximum diuretic dosage, maximum continuous diureticdosage, and minimum desired urine rate. The computer 19 may displayrecommended levels of initial and maximum diuretic levels for theoperator to select and program into the computer settings. Another inputmay be the amount of fluids during the treatment session received by thepatient through means other than the diuretic 20, such as fluid ingestedor other medical agents injected. For example, the input device 44 maybe configured to receive inputs indicating the amount of diureticinjected into the patient such as from the pump 22 for the diuretic orfrom the source 20 of the diuretic.

FIGS. 2A and 2B are graphical representations of an exemplary treatmentmethod, with FIG. 2A illustrating a diuretic dosage rate 58 (e.g., massof the diuretic per hour) dispensed over a period of time and FIG. 2Billustrating a corresponding urine output rate 62 (e.g., volume or urineper hour). In accordance with embodiments of the present technology, thetreatment method shown and described with reference to FIGS. 2A and 2Bcan enable a patient to reach and maintain a desired urine output ratewithin a predetermined period of time. Referring to both FIGS. 2A and 2Btogether, the diuretic dosage 58 and urine flow rate 62 are shown on thegraphical representation for a time period of approximately six hours,which includes an initial period referred to as Phase I or a “diureticdosage determining phase”, a subsequent period referred to as Phase IIor a “continuous diuretic dosage phase”, and a final period referred toas Phase III. As shown in FIG. 2A, Phase I is approximately one hour,Phase II is approximately three hours, and Phase III is approximatelytwo hours. In other embodiments, these times can vary and be more orless than the time durations shown in FIG. 2A. For example, Phase IIIcan include a majority of a therapy sessions and thus may be 1-36 hours.

In Phase I, an effective and safe diuretic dosage rate and/or dose isdetermined, e.g., in as short a time as possible, to cause the patientto produce urine at or above a threshold level 56. In order to quicklyincrease urine output rate 62, e.g., in less than 30 minutes, 60minutes, 90 minutes, or 120 minutes, the diuretic dosage rate 58 can beintentionally significantly higher than the dosage rate to be laterapplied to maintain urine output at or above the threshold urine rate oranother urine rate level. That is, the maximum diuretic dosage rate 58administered in Phase I may be intentionally higher (e.g., 100% higher,200% higher, 300% higher, 400% higher, 500% higher, 600% higher, orwithin a range of 100-600% higher) than the expected diuretic dosagerate 58 needed to produce the urine output rate 62 above the thresholdlevel 56 (as shown in Phase II).

During Phase I, the diuretic dosage rate 58 can be set to an initialdosage 60 that may be prescribed by the operator who inputs the dosagevia the user input device 42 of a console (e.g., the console 18; FIG. 1). The initial dosage rate 60 is a non-zero value and can be at least 50mg/hr, 75 mg/hr, 100 mg/hr, 125 mg/hr, 150 mg/hr or within a range of50-150 mg/hr (or any value therebetween). In some embodiments, theinitial dosage rate 60 may be determined by the system and be set as adefault initial dosage rate or be based on other input data specific tothe patient (e.g., the patient's weight, excess fluid weight, or otherparameter). The operator may also input other parameters of thetreatment regimen, such as a maximum allowable diuretic dosage (maximumtotal amount of diuretic and/or maximum diuretic dosage rate) 59,minimum 56 and/or maximum 78 desired urine outputs (total amount ofurine output and/or urine output rate), and/or periods for Phases I, IIand III. The initial dosage 60 of the diuretic may be selected as beingconservative and lower than needed to cause the patient to produceurine. For some patients, the initial dosage rate may be sufficient topromote a urine output rate above the threshold 56.

A computer or controller (e.g., the computer 19; FIG. 1 ) monitors andmay track urine output rate 62. Monitoring of urine output rate maystart before or when the initial low dosage rate 60 of the diuretic isgiven to the patient. The urine output rate may be monitored orcalculated in real-time or at regular intervals, such as every 30seconds, minute or multiple minutes. In some embodiments, the initialurine output is expected to be below the minimum desired urine outputrate 56. If the initial urine output rate is above the minimum desiredurine output rate 56, the operator may consider increasing the minimumdesired urine output rate or altering the amount and/or rate of diureticto be administered. In some embodiments, the computer automaticallyincreases the dosage rate of the diuretic during Phase I until the urineoutput rate is at or above the desired minimum urine rate 56. Thediuretic dosage rate may be automatically increased by the computer byadjusting operation of a diuretic pump (e.g., the diuretic pump 22; FIG.1 ). The computer may be programmed to exponentially increase the dosagerate, increase the dosage rate at a linear rate, or determine dosagerate increases based on another algorithm for increasing the dosage rateexecuted by the computer. The computer, or algorithm utilized by thecomputer, may limit the diuretic dosage rate to be no greater than amaximum diuretic dosage rate 59 entered by the operator or stored in thecomputer. In some embodiments, the diuretic dosage rate is increased insteps from the initial dosage rate 60 to a peak diuretic dosage rate 64of Phase I, such that each step increases (e.g., doubles) the amount ofincrease made in the prior step, e.g., by at least 50% or 100% (or avalue therebetween). In such embodiments, the rate of increase of thedosage rate (i.e., the slope of the diuretic dosage) may continuallyincrease with each step until the maximum dosage 64 is reached. The end66 of Phase I may be a preset time period, be determined based on whenthe peak diuretic dosage rate 64 is reached, or be a certain period(e.g., at least 2 minutes, 5 minutes, 10 minutes or within a range of2-10 minutes) after the peak diuretic dosage rate 64 is reached.

The diuretic dosage rate 58 can be increased continuously, or inincrements after a set period of time (e.g., every 2 minutes, 3 minutes,4 minutes, or 5 minutes) during Phase I, wherein each increase in thedosage is a greater than the prior increase. In some embodiments, theincrease is exponential and/or may result in a doubling of the diureticdosage rate every 15 minutes. The algorithm may be derived by fittingseries of step increases to an exponential curve defined by f(x)=a*b*x,wherein f(x) is an exponential function, a is a constant, b is apositive real number, and x is an exponent. The values for a, b and xmay be determined by experimentation and/or a physician, and may bespecifically tailored for each patient. The values for a, b and x may beset in the algorithm stored in the computer. Additionally oralternatively, such values may be based on patient specific inputs(e.g., the patient's weight, excess fluid weight, home dose of oraldiuretic, or other parameter).

As the diuretic dosage rate 58 is increased during Phase I, the computermonitors the urine output rate 62. The computer can automaticallyincrease the diuretic dosage rate 58 according to the algorithm fordiuretic dosage rate increases executed by the computer. The increasesin diuretic dosage rate can continue until the urine output rate 62reaches or exceeds the desired minimum urine rate 56. When the computerdetermines that urine output rate 62 reaches the desired minimum urineoutput rate 56, the diuretic dosage rate 58 is not further increased andthus corresponds to the peak diuretic dosage rate 64. In someembodiments, the computer may be programmed to prevent the diureticdosage rate 58 to exceed the maximum diuretic dosage rate 59 regardlessof whether the urine output reaches the desired minimum urine outputrate 56.

In some patients, the urine output rate 62 can significantly exceed thedesired minimum urine rate due to the rapidly increasing and possiblyrelatively large diuretic dosage rate 64. As discussed elsewhere herein,patients with high urine output rates may require simultaneous infusionof hydration fluid and optionally down titration of diuretic dosage ifthe urine output rate is too high, both of which may be controlled bythe computer algorithm.

Phase I may also end if a specified time period 66 for the phase expiresbefore urine output rate reaches the desired minimum urine rate. Theperiod 66 may be determined based on the maximum diuretic dosage rate59, such as no more than 5, 10, 15, or 30 minutes (or another valuetherebetween) after the maximum diuretic dosage rate 59 is reached.Phase I may be an hour, in a range of 45-90 minutes or 30-120 minutes.If the Phase I period expires, the computer may generate an alert (e.g.,from the user output device 42; FIG. 1 ) to indicate that (i) Phase Iexpired due to time and not upon reaching a maximum diuretic dosage rate59, which may indicate a lower than desired urine rate, (ii) the patientis diuretic resistant, (iii) a different diuretic may be given to thepatient and Phase I restarted, and/or (iv) an alternative fluidreduction treatment should be given to the patient, such asultrafiltration or venous pumping. Relative to current methods ofadministering a diuretic to produce urine output, embodiments of thepresent technology can cause the urine output rate to increase at afaster pace and thereby enable rapid decongestion, rapid symptom relief(E.g., dyspnea) increased fluid removal, increased sodium excretion,and/or weight reduction in a shorter time period. As previouslydescribed, conventional technologies often take conservative approachesand increase the diuretic dosage rates slowly so as to maintain morecontrol over urine output. However, doing so can cause delays of hoursor days, which thereby further exacerbate the underlying fluid overloadcondition. Unlike these conventional technologies, the relatively fastpace of embodiments of the present technology can be beneficial topatients suffering from fluid overload or pulmonary edema in a shortertime frame, as the rapid increase in diuretic dosage rate and thus urineproduction can decrease the volume of fluid in the patient'sextravascular space and pull fluid back into the intravascular spacewithin just a few hours. Moreover, as explained in detail elsewhereherein, in some embodiments, the rapid diuretic ramp can be paired witha corresponding infusion of hydration fluids to optimize net fluid losswhile also maintaining a sufficient amount of intravascular volume tomaintain proper kidney function.

With continued reference to FIGS. 2A and 2B, the regimen or method canautomatically transition to Phase II after the peak diuretic dosage rate64 is reached or the Phase I period 66 expires. Phase II may extenduntil the end of the fluid therapy and can be configured to maintain thediuretic dosage rate 58 at a constant rate or dosage level for anextended period of time 71, such as at least two hours, three hours,four hours, eight hours, 12 hours, 24 hours, 36 hours, or other setperiod. In some embodiments, Phase II is intended to allow the patient'sbody to adjust to the diuretic dosage rate 58, and generate for theentire Phase II period a urine output rate that is (i) at or greaterthan the desired minimum urine output rate 56 and/or (ii) maintainedwithin a particular range.

During Phase II, the diuretic dosage rate 58 may be set at a continuousdosage level (e.g., a maintenance dosage rate) 70, which may remainconstant during all or most of Phase II. The maintenance dosage rate 70may be the same as the peak dosage rate 64 reached during Phase I or acertain proportion of the peak dosage rate 64, such as 90%, 80%, 70%,60%, 50%, 40%, 30%, 20%, 10%, or in a range of 90% to 10% of the peakdosage rate 64. In some embodiments, the diuretic maintenance dosage 70is set based on a diuretic dosage level 72, which corresponds to adosage rate required in Phase I to reach the desired minimum urine rate56, or a total amount of diuretic required during Phase I. For example,in some embodiments, the diuretic maintenance dosage rate 70 has a valuethat is a percentage (e.g., 15%, 20%, 30%, 40%, 50%, or within a rangeof 15-50%) of a value of the total or cumulative dose (e.g., in terms ofmass or volume) delivered in Phase I. For example, if the total dose ofdiuretic delivered in Phase I is 100 mg, then the diuretic maintenancedosage rate 70 may be 20 mg/hr. Additionally or alternatively, inembodiments wherein Phase II begins due to time expiration of Phase I,the diuretic maintenance dosage rate 70 can limited to a maximum rate(e.g., no more than 40 mg/hr, 35 mg/hr, 30 mg/hr). The maintenancedosage rate 70 given in Phase II may be selected by the operator andinput into the computer. In some embodiments, the maximum diureticmaintenance dosage rate 72 may be stored in the computer such as in atable.

The regimen or method can automatically transition to Phase III at theend of Phase II. Phase III can continue until the treatment regimen iscompleted, which may occur when the net fluid removed from the patientreaches a certain volume or weight (e.g., determined automatically or bythe operator), or at the expiration of a certain period of time (e.g.,one, two or three days). Net fluid removal refers to a differencebetween the amount of fluids excreted by the patient (which maycorrespond to urine output) and the amount of fluid intake by thepatient.

During Phase III, the computer may adjust the diuretic dosage rate 76to, for example, (i) maintain the urine output rate 62 within a desiredrange 77, (ii) adjust the diuretic dosage rate 76 to maintain the urineoutput rate 62 above a desired minimum output rate 56, and/or (iii) keepthe urine output rate 62 below a maximum urine output rate 78. Thedesired range 77 may be automatically calculated based on the averageurine output rate during Phase II, such as a range of 80% to 120% of theaverage urine output rate during Phase II. The desired range 77 may be arange centered on 525 ml/hr, e.g., with the lower end of the range at475 ml/hr and the high end at 575 ml/hr. Alternatively, the desiredrange or desired minimum and maximum urine output rates may beparameters input by the operator into the computer or may be stored inthe computer. The diuretic dosage rate for Phase III may also be thekept at the same dosage rate as the continuous dosage rate 70 for PhaseII, such that Phases II and III operate in similar manners. Further, ifthe urine output level 62 falls below a desired minimum urine outputlevel (which may or may not be the same level as in Phase I), thecomputer may automatically restart Phase I or issue an alert or reportfrom the computer suggesting that Phase I be restarted, e.g., in orderto determine a more optimal diuretic maintenance dosage rate. Forexample, if the urine rate falls below 325 ml/hr for a period of threehours, the computer may restart Phase I. Similarly, if the urine outputrate repeatedly cycles between below 325 ml/hr and above 325 ml/hr suchthat the net fluid reduction is effectively too low, the computer mayrestart Phase I. To determine if the net fluid reduction is too low, thesoftware may calculate a “debt” value, defined as the area below 325ml/hr and above the current urine output rate over a given period oftime, such as 3 hours. For instance, if the urine output rate was 300ml/hr for an hour, the “debt” would be 25 ml (325 minus 300). If the“debt” exceeds a set value over a set amount of time, for instance 150ml of debt over 3 hours, the computer may automatically restart Phase Ior issue an alert or report from the user output device 42 suggestingthat Phase I be restarted.

During Phase III, the computer may automatically reduce the dosage ofthe diuretic, such as a 20%, 35%, 55%, 75% or more, of the currentdosage rate, if the urine output rate exceeds a high threshold level.If, after a certain period, such as one hour, the urine output rateremains too high after the diuretic dosage rate is reduced, e.g.,remains above the threshold level, the computer may automatically stopor down-titrate infusion of the diuretic for a certain period. Forexample, if the urine output rate exceeds 625 ml/hr for an hour, thecomputer may automatically stop infusion of the diuretic or reduce thediuretic dosage rate to the minimum dosage rate for a predefined period(e.g., 50 minutes to an hour). If the urine output rate drops below aset threshold in response to the reduction in diuretic dosage rate, thecomputer may resume continuous diuretic infusion at a percentage of theprevious continuous dosage rate. The reduction may be based on theduration of stopped diuretic dosage rate that had elapsed when the urineoutput rate dropped below the threshold level. If the predefined periodelapses and the urine output rate remains above the threshold level,then the continuous dosage rate may be resumed at a rate reduced by apredefined amount, such as a 25 percent reduction from the continuousdosage rate prior to the stopping of the injection.

In addition to controlling the diuretic dosage rate, the computer mayexecute a program for controlling infusion of the hydration fluid fromthe hydration fluid source 24 into the patient. The computer may controlthe infusion of the hydration fluid by controlling the infusion pump(e.g., the infusion pump 26; FIG. 1 ) based on an algorithm to achieve adesired net fluid reduction in the patient.

FIG. 3 is a graphical representation showing a relationship betweenurine output, hydration fluid infusion, and net fluid loss, inaccordance with embodiments of the present technology. Stateddifferently, FIG. 3 illustrates an exemplary representation for howembodiments of the present technology automatically control thehydration fluid infusion rate 80 based on the urine output rate 82 toachieve a net fluid change rate 84 in a patient. The control of thehydration fluid infusion rate 80 can be performed simultaneously to thecontrol of diuretic dosage during Phases I, II and/or III.

The urine output rate 82 is expected to initially increase during PhaseI and thereby result in an increase in the net fluid reduction rate. Insome embodiments, the hydration fluid infusion rate 80 can match theurine output rate 82 until a predetermined volume (e.g., at least 150ml, 200 ml, 250 ml, 300 ml, 400 ml, 500 ml, or within a range of 150-500ml) of urine has been measured, or a particular period of time (e.g., atleast 60 minutes) has elapsed. In some embodiments, the net fluidreduction rate 84 may substantially equal the urine output rate 82 untilhydration fluid is infused into the patient. The computer may determinethat hydration fluid is to be added if and when the net fluid reductionrate 84 falls below a threshold minimum value 86 or the urine outputrate 82 exceeds a threshold urine output rate 88. These threshold valuesmay be input by the physician into the user input device 40 or stored(e.g., as defaults) in the computer. These threshold values need notoccur simultaneously as shown in FIG. 3 , but are related and thus arelikely to happen at approximately the same time. Alternatively, thecomputer may cause hydration fluid to be infused at near the same timethat the diuretic begins to be infused, including when Phase I or adiuretic dosage determining phase is implemented (e.g., reimplemented).Once one or both of the threshold values 86, 88 are reached, thecomputer may automatically initiate the infusion of hydration fluid 80by actuating an infusion pump (e.g., the hydration infusion pump 26;FIG. 1 ) to pump hydration fluid from a fluid source (e.g., the fluidsource 24; FIG. 1 ) into the patient. The rate of hydration fluid 80infusion may be calculated or determined by the computer based on, forexample, a difference between the current urine output rate and adesired net fluid balance rate 90. For example, if the desired net fluidreduction rate is 200 (ml/hr) and the urine output rate is 400 ml/hr,then the computer may automatically control the infusion of thehydration fluid at a rate of 200 ml/hr.

The computer may adjust the infusion rate 80 of the hydration fluid tomaintain a desired net fluid reduction rate 84, such a net fluid balancerate 84 that is constant, between a particular range, or below (i.e.,more negative than) a threshold. During an initial phase or period 85,the hydration fluid may be infused for an hour or until a predeterminedamount (e.g., at least 500 ml) of hydration fluid is infused, whicheverevent occurs first. During the initial phase 85, the computer may matchthe rate of increase in urine output 82 with the rate of increase in thehydration fluid infusion 80. Increasing the hydration fluid at the samerate of increase of urine output infuses into the vascular system asubstantial amount of hydration fluid. Hydration fluid includes arelatively high concentration of sodium and/or chloride as compared tothe typical respective sodium and chloride concentration in urine, andthus infusing hydration fluid into the vascular system increases thesodium and/or chloride level in the blood, even as the patient isexcreting urine. Similarly, the hydration fluid may add potassium to theblood at rates greater than the discharge of potassium from urine. Indoing so, the initial period 85 allows the sodium, chloride, and/orpotassium levels in the blood to be artificially increased whichprovides a safeguard against sodium, chloride, and/or potassiumdepletion in the patient if the blood volume drops to relatively lowlevels during the treatment.

After the initial phase 85, the computer may increase the hydrationfluid rate 80 at a rate 94 less than the current rate increase 96 ofurine output rate 82 (e.g., a proportion of the current rate increase 96of about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or within arange of 10%-95%). Alternatively, the computer may reduce the rate ofincrease 94 for the hydration fluid in response to the urine output rate82 exceeding a first threshold value 92 (e.g., 400 ml/hr, 420 ml/hr, 440ml/hr, or within a range of 400-440 ml/hr), above which hydration fluidrate 80 is not further increased. If and while the urine output rate 82exceeds a first threshold 92, the computer may reduce further the rateof increase 94 in the hydration fluid 80 to significantly less than thecurrent rate of increase 96 of the urine output 82. For example, whilethe urine output rate 82 is above the first threshold 92, a further rateof increase 96 in the urine output rate 82 will be matched by a furtherrate of increase 94 in the hydration fluid infusion rate 80, which isincreased at only one-half, or in a range of one quarter tothree-fourths, the rate of increase 96 of the urine output rate 82.Simultaneously, the rate of decrease 102 of net fluid reduction 84increases due to the greater rate of increase of urine output ascompared to the lower rate of increase of hydration fluid. As describedelsewhere herein, adjusting (e.g., increasing or decreasing) thehydration fluid rate (or rate of increase of the hydration fluid rate)less than that of the urine output rate can cause net fluid removal ofsalt within the patient, as well as net fluid loss.

If the urine output rate 82 continues to increase and exceeds a secondthreshold 98 (e.g., at least 500 ml/hr, 1020 ml/hr, or a range of500-1020 ml/hr), the computer may automatically cease further increasesin the hydration fluid rate 80. While the urine output rate 82 is abovethe second threshold 98, the computer may maintain the hydration fluidrate 80 at a constant rate 100 (e.g., 200 ml/hr) regardless of furtherincreases in the urine output rate 82. Moreover, the increase in the netfluid reduction rate 84 has an advantage of reducing the period neededto reach a desired total net fluid reduction. The rate 104 of net fluidreduction increases due to the increase in the urine output rate 82 andthe constant hydration fluid rate 80.

Setting the threshold 98 for a maximum urine output beyond whichhydration fluid is not further increased is based, in part, on a desireto avoid excessive sodium levels in the patient. The sodiumconcentration in urine may change throughout the treatment as thephysiological state of the patient changes but less than (e.g.,approximately one-half) the sodium concentration of a saline solutionthat is expected to be used as the hydration fluid. At high infusionrates of the hydration fluid, the net sodium increase to the patient maybecome excessive over the course of an hour or more of treatment. Toreduce the sodium added to the patient, an upper limit 100 is applied tothe hydration fluid rate 80. This limit may be indirectly imposed bysetting a threshold maximum urine output rate 98 beyond which thehydration fluid rate 80 is not increased as the urine rate increasesbeyond the threshold 98.

As mentioned above, the computer may automatically act to reduce highurine output rates, such as above thresholds 92 and/or 98, by reducingthe diuretic dosage. The diuretic dosage rate may be increased to dosagelevels previously considered inappropriate for fluid reductiontreatments. Embodiments of the present technology can administereddiuretic at these high levels due to (i) the automatic reduction in thediuretic dosage in response to the urine output rate 82 exceedingthreshold levels 92, 98, and/or (ii) hydration fluid infusion directlyinto the vascular system of a patient. The infusion of the hydrationfluid reduces the risk that the blood volume in the patient will becometoo low due to a high diuretic dosage. Thus, the diuretic dosage levels64, 70, 76 described with reference to FIG. 2A may be substantiallygreater than maximum dosage levels conventionally viewed as appropriateand approved.

The computer may store certain limits on the treatment, such as adefault fluid balance rate and a maximum net fluid loss. The default netfluid balance rate may be a negative 220 ml/hr or in a range of 150ml/hr to 260 ml/hr. The maximum net fluid loss limit may be 5 liters(5,000 ml), at which point the computer issues a report or alarm, andmay stop injecting the diuretic, at least temporarily. An operator mayrespond to the alarm by entering higher maximum net fluid loss limit,such as in increments of 1 liter. In response to the higher maximum netfluid loss limit, the computer may resume Phase III.

A clinical study utilizing embodiments of the present technologyconsistently reduced the fluid volume in patients faster thanconventional standards of care. In previous studies of this patientpopulation, only 47% of patients receiving standard of care achieve agoal of removing four to five liters of fluid volume and it typicallytakes five days of hospitalization to achieve. In comparison,embodiments of the present technology resulted in removing a net of fourto five liters of fluid volume in 24 hours or less. The urine sodiumdata from this study confirms that embodiments of the present technologyalso remove significant amounts of salt via high-sodium urine from thepatients in addition to net decrease in fluid volume. The urine ofpatients receiving the conventional standard of care removesubstantially only hypotonic urine (e.g., 60-70 mmol sodium). Thegreater removal of salt achieved via embodiments of the presenttechnology may result in less drive for the patient to reaccumulatefluid after discharge and result in a significant reduction inrehospitalization rates.

In addition to automating delivery of diuretic and hydration fluidsbased on urine output, embodiments of the present technology mayoptimize net fluid volume removal; reduce time needed to achieve desirednet fluid removal by allowing physicians to use higher doses or dosagerates of diuretics earlier in treatment compared to the standard ofcare; avoid or reduce risk of adverse events such as over-diuresis,dehydration, or intravascular depletion; quickly assess if a patient isdiuretic resistant; and provide a record of treatment data. Embodimentsof the present technology aim to obtain an average net fluid removalrate (average rate of urine released minus average rate of hydrationfluid introduced) of at least 225 ml/hr, which provides 3.4 liters perday of net fluid volume removal based on introducing 2 liters of fluidper day orally or through IV infusion. This rate of fluid removal whilereplacing sodium may allow a reduction in length of stay (LOS), as wellas enable enhanced decongestion.

To achieve these objectives, embodiments of the present technology havea short diuretic dosage determining phase to determine an appropriatecontinuous diuretic infusion rate, which is then used in a fluidreduction phase during which urine output is continuously monitored andused to assess if the diuretic infusion rate continues to be suitableand to adjust the diuretic infusion rate accordingly. Concurrently, thealgorithm controls infusion of hydration fluid to replace a portion ofthe sodium and fluid removed. The rate of infusion of hydration fluid isat least in part a function of the rate of urine output.

FIG. 4A shows a flowchart of a method 400 that controls a rate ofinfusion of diuretic during a diuretic dosage determining phase (processportion 402). The method 400 can be part of the algorithm describedelsewhere herein. The diuretic dosage determining phase can correspondin whole or in part to the diuretic dosage determining phase describedwith reference to FIG. 2 . The diuretic dosage determining phase cancorrespond to the beginning of fluid management therapy, or be triggeredwhen one of more of a set of conditions is met (e.g., the urine outputdrops below a threshold). The start of the diuretic dosage determiningphase may be triggered manually by a user, e.g., if the user thinks thediuretic dosage rate is too low or the urine output is too low and wantsto reassess the diuretic dosage. In this regard, the underlyingphysiological state of the patient often changes over the course offluid therapy of hospitalization, and therefore the diuretic dosagerequired to cause the patient to produce a desired urine output rate mayneed to be adjusted by repeating the diuretic dosage determining phase.

As shown in FIG. 4A, the diuretic dosage determining phase can begin bysetting a diuretic dosage rate (process portion 404). The initialdiuretic dosage rate can be set relatively low (e.g., no more than 60mg/hr, 80 mg/hr, 100 mg/hr, 120 mg/hr, or within a range of 60-120mg/hr), and/or be based on factors specific to the patient (e.g., sex,age, weight, historical treatment, etc.). Once a diuretic dosage rate isprovided, the system (e.g., the fluid management system 10, the diureticsystem 14, and/or any subsystems thereof; FIG. 1 ) can check whether theurine rate is above a predetermined threshold (process portion 406). Thepredetermined threshold can be 200 ml/hour, 300 ml/hour, 400 ml/hour,450 ml/hour, 500 ml/hour, 525 ml/hour, 550 ml/hour, or within a range of200-550 ml/hour. If the urine rate is not above the predeterminedthreshold, the system can check whether a predetermined amount of time(e.g., ramp time) has elapsed (process portion 408). The ramp time canbe no more than 40 minutes, 50 minutes, 60 minutes, 70 minutes, or 80minutes, or within a range of 40-80 minutes. If the ramp time haselapsed without the urine rate exceeding the predetermined threshold,the system may adjust the diuretic dosage rate on an iterative basisafter an increment time (e.g., every 2 minutes, 3 minutes, 4 minutes, orother set interval). The adjusted diuretic dosage rate can be increasedlinearly or exponentially until either the urine output rate exceeds thepredetermined threshold or the ramp time has elapsed. The diureticdosage rate for a given minute t may calculated with the formula:A*(2{circumflex over ( )}(t*B))+C, where A, B, and C are constantvalues. In some embodiments, an exponential increase may optimize speedof finding a suitable dosage rate safely, whereas a slower increase(e.g., a linear increase) can work to find the suitable dosage rate butmay take longer. In some embodiments, each incremental step increase isgreater than the immediately previous step, such that the diureticdosage rate is doubled over a certain time period (e.g., every 5minutes, 10 minutes, 15 minutes, 20 minutes, or within a range of 5-20minutes). In doing so, the system enables the urine rate to increase inan efficient and rapid manner, thereby enabling excess fluid to beremoved from the patient as soon as possible and/or identify whether thepatient has a condition (e.g., is diuretic resistant) as soon aspossible. In some embodiments, the diuretic may be limited to a maximumdose amount (e.g., 200 mg for furosemide) over the ramp time. In thisregard, the system can be configured to only provide diuretic dosagesthat are within health care regulations and can be safely delivered.

If the urine rate, in response to the increased diuretic dosage, isabove the predetermined threshold, then a value of the adjusted dosagerate (e.g., the initial rate for the subsequent continuous infusionphase) is set to a predetermined percentage (e.g., 10%, 15%, 20%, 25%,30%, or within a range of 10-30%) of a value of the total dose deliveredto the patient at that time (process portion 412). For example, if thetotal dose delivered is 100 mg, then the adjusted dosage rate may be 20mg/hr if the predetermined percentage is 20%. Similarly, if the ramptime elapses before the urine rate exceeds the predetermined threshold,the value of the dosage rate can be set to the predetermined percentageof the value of the total dose delivered to the patient at that time(process portion 414). The percentage may be based on a pharmacokineticcharacteristic of the particular diuretic being infused. For example, ifthe diuretic is furosemide, the fraction may be 20%, and if 50 mg offurosemide is infused in 60 minutes, then the calculated continuousdiuretic dosage rate may be 10 mg/hr. This concept is described inadditional detail with reference to FIG. 4B. Decreasing the diureticdosage rate rapidly to a percentage of the total dose delivered, and/orless than the immediately previous dosage rate or average dosage rateover the previous 5-10 minutes, can enable the urine rate to decreaseits rate of increase (e.g., to approach a slope of zero) but withoutactually decreasing the urine output itself. Additionally oralternatively, such a diuretic dosage decrease can enable the urine rateto be maintained at a predetermined rate and/or within a predeterminedrange.

Once the dosage rate is set, per process portion 412, the system maydetermine whether the average urine rate over a predetermined historicaltime (e.g., 5 minutes, 10 minutes, 15 minutes) is greater than thepredetermined threshold (process portion 416). Process portion 416 canserve as an additional verification that the urine rate is high enoughto proceed to other operating phases. For example, if the urine ratepeaked over the predetermined threshold for a moment but was notconsistently over the predetermined threshold, process portion 416 wouldprovide an alarm and/or prevent the system from proceeding to asubsequent operating phase. If the average unit rate is over thepredetermined threshold, the system can proceed to another operatingphase, such as the continuous infusion phase (e.g., described withreference to FIG. 5 ). If the average urine rate is not greater than thepredetermined threshold, the diuretic dosage rate may be set to theimmediately previous rate (process portion 418) and then returned toprocess portion 406, e.g., to re-ramp the diuretic dosage rate toincrease the urine rate.

The diuretic dosage determining phase enables the diuretic dosage rateto be ramped quickly and to a high dosage rate, relative to currentsystems and methods, thereby allowing a patient's urine rate to berapidly increased to be above a minimum threshold. Unlike currentsystems and methods which do not quickly ramp the diuretic dosage, butrather slowly increase the diuretic dosage to err on the side of safety(e.g., to avoid over-diuresis), embodiments of the present technologycan ramp the diuretic dosage rate in a relatively fast manner, becausethe risk of diuresis or related issues can be mitigated, e.g., by theability of these same embodiments to automatically decrease the diureticdosage rate once a certain urine output is reached and/or controlhydration fluid infusion. In doing so, embodiments of the presenttechnology can efficiently cause net fluid loss from the patient, whilealso setting a net fluid loss limit (e.g., 100 ml/hr) to ensure that asufficient amount of intravascular volume is maintained by the patient.This inhibits the drop in cardiac output and renal perfusion that isoften observed when urine output rates approach elevated levels forheart failure patients.

FIG. 4B is a graphical representation 450 showing a relationship betweendiuretic dosage rate 460 and total diuretic delivered 470, in accordancewith embodiments of the present technology. The concepts shown anddescribed in FIG. 4B can apply to other aspects of the presenttechnology that relate to the diuretic dosage determining phase,diuretic ramp, and associated features. As shown in FIG. 4B, thediuretic dosage rate 460 can be ramped from an initial rate of about 75mg/hr to a final rate of about 447 mg/hr within a time period of 60minutes. As such, the diuretic dosage rate 460 can increase by about500% over the time period. As also shown, the diuretic dosage rate 460can effectively double within a time period of about 20 minutes.

The total diuretic delivered 470 (mg) corresponds to the cumulativeamount of diuretic that has been delivered up to that point in time. Aspreviously described (e.g., with reference to FIG. 4A), a value of thetotal diuretic delivered 470 can be used to determine the value or setpoint for the diuretic after the urine output rate of the patientreaches a predetermined threshold. For example, once the urine outputrate reaches the predetermined threshold (e.g., 400 ml/hour, 450ml/hour, 500 ml/hour, 525 ml/hour, 550 ml/hour, or within a range of400-550 ml/hour), a value of the diuretic dosage rate may be set to be apercentage (e.g., 20%) of a value of the total diuretic delivered 470 upto that point in time. As shown in FIG. 4B, the diuretic dosage ratesetpoint 480 corresponds to 20% of the value of the total diureticdelivered 470. It is noted that the values shown in FIG. 4B may be usedfor a furosemide diuretic. Use of other diuretics may require differentdosage rates, but similar general principles as those described hereinwould apply.

II. Reramp or Rapid Increase of Diuretic Dosage Rate

FIG. 5 is a flowchart 500 of a continuous diuretic delivery phase oranother phase (e.g., a fluid reduction phase), in accordance withembodiments of the present technology. As described elsewhere herein,the continuous delivery phase 502 can occur after the diuretic dosagedetermining phase, or more specifically after the urine output rate hadpreviously been above a predetermined threshold. The continuous infusionphase may coincide with the fluid reduction phase, during whichhydration fluid is infused at a rate less than the urine output rate tothereby cause net fluid loss. During the continuous delivery phase, theurine rate is checked and/or obtained (process portion 504) on a regularbasis (e.g., every minute) to ensure the urine rate is at expectedlevels and responding to the diuretic dosage. As part of this check, thesystem can determine whether the average urine output over a previoushistorical time (e.g., the previous 10 minutes, 15 minutes, 20 minutes)is greater than a first threshold amount (e.g., 20 ml, 25 ml, 30 ml, 40ml) (process portion 506). If the average urine output is not greaterthan the first threshold, an alert message may be given (e.g. displayedon the User Output Device 42; FIG. 1 ) to inform the user of very lowurine rate and risk of blocked Foley catheter or other equipmentmalfunction (process portion 508). Subsequently, the average urine ratecan be checked against a set of conditions to determine if urine rate islow (process portion 510) and/or if a ramp (e.g., a reramp) of thediuretic dosage is warranted. If any one of the set of conditions is metand thus urine output is determined to be low, the system may proceed toramp or reramp the diuretic dosage to establish (e.g., by returning tothe diuretic dosage determining phase), or reestablish the urine rateabove a minimum threshold. If the urine rate is not low, the system mayoperate in a loop to continuously monitor urine rate.

The set of conditions can include determining whether (i) the averageurine rate is below a predetermined threshold rate (e.g., 250 ml/hr, 300ml/hr, 325 ml/hr, 350 ml/hr, 400 ml/hr, or within a range of 250-400ml/hr) for a predetermined period of time (e.g., 2 hours, 2.5 hours, 3hours, or within a range of 2-3 hours), or (ii) more than apredetermined amount (e.g., 100 ml, 125 ml, 150 ml, 175 ml, or within arange of 100-175 ml/hr) of debt has accumulated over the predeterminedperiod of time. “Debt” can be defined as the area on a plot between theurine output rate and a set rate (e.g., 325 ml/hr), and essentiallyrepresents how much of and for how long the urine output rate has beenbelow the set rate. The debt can accumulate unless an associated counteris reset. For example, if the patient released urine at a constant rateof 300 ml/hr over 3 hours the debt will be 75 ml for a set rate of 325ml/hr. The lower the urine output rate the greater the debt. If theurine output rate rises above the set rate, debt is not accumulated, butis still considered until a certain amount of time (e.g., 3 hours) havepassed since the debt was accumulated. Calculating debt in such a mannerenables embodiments of the present technology to respond to a low urineoutput rate more quickly than if debt calculation was not utilized.

If any one of the set of conditions is met and thus the average urinerate is too low, the user may be asked to confirm that a reramp ordiuretic dosage determining phase is to be implemented (process portion514). Regulations may require that the user's confirmation be receivedprior to beginning the reramp. If the user does not agree to the reramp,the counters for the set of conditions may be reset. That is, the debtaccumulated and the period of time used to calculate whether the urinerate is below the predetermined threshold can be reset to zero. If theuser agrees to the reramp, the ramp can be started at the previousdiuretic dosage rate (process portion 518), e.g., where the previousramp finished. In such embodiments, the diuretic dosage rate begins atthe final rate in the previous ramp and the total elapsed ramp timeaccumulates on the previous total elapsed ramp time. This concept isshown and described in additional detail with reference to FIG. 6 .After starting the ramp, the system determines whether the urine rate isabove a predetermined threshold (e.g., 400 ml/hour, 450 ml/hour, 500ml/hour, 525 ml/hour, 550 ml/hour, or within a range of 400-550 ml/hour)or whether a predetermined amount of time (e.g., the ramp time) haselapsed (process portion 520). If not, the system may adjust thediuretic dosage rate after an increment time (process portion 524), asdescribed elsewhere herein. If the urine rate is above the predeterminedthreshold, the diuretic dosage rate can be set to a predeterminedpercentage (e.g., 10%, 15%, 20%, 25%, 30%, or within a range of 10-30%)of the total dose delivered to the patient at that time (process portion522). Subsequently, the counters for the set of conditions are reset(process portion 516), and the system may revert to process portion 504.

In some embodiments, the user may check over the equipment and decide tomanually adjust the continuous diuretic dosage rate, or trigger reentryto the diuretic dosage determining phase. If reentry is manuallytriggered, the patient can receive up to 60 minutes of total elapsedramp time, which may be the highest continuous dose allowed per theregulatory agencies. As such, if the total elapsed ramp time is morethan 55 minutes, then there may be little benefit to reentering a ramp.In such embodiments, a 3-hour average urine output rate is reset and aurine debt is set to 0 and the algorithm returns to process portion 504.However, if the total elapsed ramp time is less than or equal to 55minutes, the user may be asked to confirm a ramp restart (processportion 514).

FIG. 6 is a graphical representation 600 of diuretic dosage rate 605 andcorresponding urine output rate 610, in accordance with embodiments ofthe present technology. The graphical representation 600 generallyillustrates the embodiments described with reference to FIG. 5 .Initially, the diuretic dosage rate 605 is increased or ramped until theurine rate 610 reaches a predetermined threshold, which in this instanceis approximately 525 ml/hr. Once the predetermined threshold is reached,the ramp of the diuretic dosage rate 605 ceases (e.g., at point 620),and the diuretic dosage rate 605 is set to a percentage (e.g., 10%, 15%,20%, 25%, 30%, or within a range of 10-30%) of the total diuretic dosedelivered to the patient up to that point in time. For the embodimentillustrated in FIG. 6 , the ramp of the diuretic dosage rate 605completes at the point 620 after 50 mg of diuretic has been delivered,and the diuretic dosage rate 605 is thereafter set to 10 mg/hr or 20% ofthe total diuretic infused up to that point. The decreased diureticdosage rate 605 can then be provided at the continuous rate of 10 mg/hruntil the system causes the dosage rate 605 to be adjusted, e.g., inresponse to the urine rate dropping and/or a regulatory limit being met.

As illustrated by line 624, the urine rate 610 may decrease to a lowerurine rate, as illustrated by line 626. This drop is urine rate 610 maybe due to a change in the patient's response to the diuretic or othercondition. Though the urine rate after line 624 is now below thepredetermined threshold of 525 ml/hour, the diuretic dosage rate may notbe immediately adjusted. Instead, as described elsewhere herein (e.g.,with reference to FIG. 5 ), the diuretic dosage rate 605 may be adjustedonly after (i) the urine rate is below another predetermined threshold(e.g., a second predetermined threshold) (e.g., 250 ml/hr, 300 ml/hr,325 ml/hr, 350 ml/hr, 400 ml/hr, or 250-400 ml/hr) for a predeterminedperiod of time (e.g., 2 hours, 2.5 hours, or 3 hours), or (ii) more thana predetermined amount (e.g., 100 ml, 125 ml, 150 ml, 175 ml) of debthas accumulated over the second predetermined period of time. Usingthese time-weighted average measurements of urine rate, as opposed to aninstantaneous drop below the first predetermined threshold, to initiatea reramp of the diuretic dosage can prevent unnecessary reramps when,for example, the drop in urine rate 610 is due merely to a blocked Foleycatheter, temporary faulty sensor, or other related short-term measure.At point 628, the system determines that the average urine rate has beenbelow the second predetermined threshold for 3 hours. As a result, areramp of the diuretic dosage rate 605 is initialized and the dosagerate is set to the rate at which the previous ramp ceased (as shown atpoint 630), in this instance approximately 180 mg/hr. The diureticdosage rate 605 is then ramped according to the same conditionsdescribed elsewhere herein (e.g., with reference to FIGS. 2A-4 ). Insome embodiments, the initial diuretic dosage rate 605 for the rerampcan be set to a rate below (e.g., 10%, 20%, 30%, or 10-30% below) therate at which the previous ramp ceased. Once the urine output ratereaches the predetermined threshold, the ramp of the diuretic dosagerate 605 ceases (i.e., at point 632), and the diuretic dosage rate 605is set to a percentage, in this instance 20%, of the total diuretic dosedelivered to the patient up to that point. For the embodimentillustrated in FIG. 6 , the ramp of the diuretic dosage rate 605completes at the point 632 after 50 mg of diuretic has been deliveredvia the second ramp or a total of 100 mg of diuretic (i.e., 50 mg fromthe second ramp and 50 mg previously delivered to the patient during theprevious ramp ending at point 620), and the diuretic dosage rate 605 isthereafter set to 20 mg/hr or 20% of the total diuretic infused up tothat point. The decreased diuretic dosage rate 605 can then be providedat the continuous rate of 20 mg/hr until the system causes the dosagerate 605 to be adjusted.

III. Down-Titration or Decrease of Diuretic Dosage Rate

FIG. 7 is a flowchart 700 illustrating down-titration of a diureticdosage rate, in accordance with embodiments of the present technology.Fluid removal from a patient can often lead to physiological changes,which may cause an increased response to a diuretic dosage. In suchinstances, the urine rate may remain higher than clinically desired,which when left untreated over long periods of time can causeelectrolyte loss and/or hypotension. Additionally, in such instances, itmay also be desired to not simply cease providing diuretic to thepatient, as doing so could unnecessarily cause fluid therapy to have tobe restarted and thus increase the overall time needed to remove a netamount of excess fluid. To mitigate such issues, embodiments of thepresent technology can include a methodology for down-titrating (i.e.,reducing) the diuretic dosage without setting the diuretic dosage tozero.

As shown in FIG. 7 , the flowchart 700 begins by providing a diuretic toa patient at a dosage rate (process portion 702), as described elsewhereherein. The system then determines whether each one of a set ofconditions is met, and if so down-titrates the diuretic dosage. The setof conditions can include determining whether the average urine rate isgreater than a predetermined rate for a first period of time (e.g., 2hours, 3 hours, 4 hours, or within a range of 2-4 hours) (processportion 704). The predetermined rate can be dependent on whetherhydration fluid is being infused to the patient. If hydration fluid isbeing infused to the patient, the predetermined rate can be 900 ml/hr,950 ml/hr, 1025 ml/h, 1100 ml/hr, or within a range of 900-1100 ml/hr.If no hydration fluid is being infused to the patient, the predeterminedrate can be 400 ml/hr, 450 ml/hr, 525 ml/hr, 600 ml/hr, or within arange of 400-600 ml/hr. The set of conditions can further includedetermining whether an average rate of increase of the urine rate (e.g.,a positive slope) is greater than a predetermined rate of change (e.g.,30 ml/hr², 40 ml/hr², 50 ml/hr², 60 ml/hr², 70 ml/hr², or within a rangeof 30-70 ml/hr²) for a second period of time (e.g., 1 hour, 2 hours, 3hours, or within a range of 1-3 hours) (process portion 706). The set ofconditions can further include determining whether the diuretic dosagerate is greater than a predetermined dosage rate (e.g., 8 mg/hr, 10mg/hr, 12 mg/hr, or within a range of 8-12 mg/hr) (process portion 708).In some embodiments, if any one of the set of conditions is not met, thesystem will not down-titrate the diuretic dosage and will revert toprocess portion 702. If each one of the set of conditions is met, thesystem will proceed to decrease the diuretic dosage rate by apredetermined. In some embodiments, the system may proceed to decreasethe diuretic dosage per process portion 710 if two of the threeconditions are met.

In some embodiments, by requiring all or a majority of the set ofconditions to be met, the system avoids unnecessarily decreasing thediuretic dosage rate, thereby allowing urine rates to remain high andpreventing fluid therapy from being unnecessarily interrupted. Forexample, whereas other methodologies may interrupt fluid therapy anddecrease the diuretic dosage rate when the urine rate is merely above apredetermined threshold, embodiments of the present technology may onlydecrease the dosage rate (per process portion 710) when the urine rateis both high and increasing. Stated differently, such a methodology canprevent the diuretic dosage rate from being unnecessarily decreased whenurine rates are high (e.g., above the predetermined rate) temporarilybut are trending downward to eventually be below the predetermined rate.In doing so, embodiments of the present technology can also prevent orinhibit over-diuresis or excess fluid loss and/or electrolyte loss, aswell limit unnecessary exposure of the patient to additional medicalagents. Additionally or alternatively, down-titrating the diureticdosage rate, as opposed to ceasing the diuretic dosage can bebeneficial, as fluid therapy can be continued (albeit at lower urinerates) without the need to restart completely. Additionally oralternatively, by mitigating the potential hazard of diureticovershooting (e.g., when ramping the diuretic during the dosagedetermining phase) and limiting overexposure of the patient to thediuretic, there may be additional regulatory benefits to having thedown-titration methodology.

If the set of conditions are met, the system can decrease the diureticdosage rate by a predetermined percentage (e.g., 20%, 25%, 30%, orwithin a range of 20-30%) for a third period of time (e.g., 2 hours, 3,hours, 4 hours, or within a range of 2-4 hours) (process portion 710).After decreasing the diuretic dosage, the system checks whether thethird period of time has elapsed (process portion 712), and if so resetsthe counters associated with the set of conditions (process portion714). In such embodiments, the diuretic dosage rate can remain at thedown-titrated levels or be adjusted based on the subsequent operatingphase of therapy. If the third period of time has not elapsed, thesystem may determine whether the average urine rate is greater than adown-titration threshold (process portion 720). The down-titrationthreshold may be based on the predetermined rate used in process portion704. For example, the down-titration threshold can be 100 ml/hr lessthan the predetermined rate. In such embodiments, the down-titrationthreshold can be 800 ml/hr, 850 ml/hr, 925 ml/h, 1000 ml/hr, or within arange of 800-1000 ml/hr when hydration fluid is being infused, and 300ml/hr, 350 ml/hr, 425 ml/hr, 500 ml/hr, or within a range of 300-500ml/hr if no hydration fluid is being infused. If the average urine rateis less that the down-titration threshold, the diuretic dosage rate canbe adjusted (e.g., increased) based on the elapsed time at that momentin time. In some embodiments, the predetermined percentage that thediuretic dosage rate decreased per process portion 710 is reduced by thefraction of the third period that has elapsed. For example, assuming thepredetermined percentage was 25%, if the diuretic dosage rate dropsbelow the down-titration threshold 90 minutes after the down-titrationbegan (i.e., half of the third period of time of 180 minutes), thediuretic dosage rate would then be increased to be only half of thepredetermined percentage, or 12.5%. After the diuretic dosage isadjusted per process portion 720, the system can reset the countersassociated with the set of conditions (process portion 714), aspreviously described.

FIG. 8 is a graphical representation 800 of down-titrating a diureticdosage rate 805, in accordance with embodiments of the presenttechnology. The graphical representation 800 generally illustrates theembodiments described with reference to FIG. 7 . As shown in FIG. 8 ,the diuretic dosage rate 805 is initially steady at a rate ofapproximately 20 mg/hour, and the urine rate 810 is increasing at a rategreater than 50 ml/hr². Approximately at point 820, the urine outputexceeds 1025 ml/hr. At point 822, each one of the set of conditionsdescribed with reference to FIG. 7 is met. That is, (i) the averageurine rate 810 has been above a predetermined rate of 1025 ml/hr for afirst period of time of 3 hours, (ii) the average rate of change of theurine rate is above a predetermined rate of change of 50 ml/hr², and(iii) the diuretic dosage rate is above a predetermined dosage rate of10 mg/hr. As such, the diuretic dosage rate at point 822 is decreased bya predetermined percentage, in this instance 25%, from 20 mg/hr to 15mg/hr for a period of time, in this instance 3 hours.

Decreasing the diuretic dosage rate 805 causes the urine rate to drop,as illustrated by portion 824. Once the urine output reaches adown-titration threshold of 925 ml/hr at point 826, the diuretic dosagerate is increased. Since the down-titration threshold was reached onehour after the down-titration event (i.e. ⅓ of the 3 hour period oftime), the diuretic dosage rate is subsequently set to be ⅓ (33%) of theoriginal 25% reduction or 8.3% less than the original diuretic dosagerate of 20 mg/hr. Accordingly, the diuretic dosage rate is set toapproximately 18.3 mg/hr. Point 828 corresponds to 3 hours of elapsedtime since the down-titration event, and thus at that time thedown-titration check is re-engaged. Stated differently, thedown-titration feature is disabled for a period of time, in thisinstance 3 hours, after a down-titration event occurs.

FIG. 9 is a graphical representation 900 of the relationship betweenurine output rate 905, hydration fluid infusion rate 910, and net fluidbalance 915, in accordance with embodiments of the present technology.As described elsewhere herein, embodiments of the present technologyenable the urine rate 905 of a patient to be rapidly increased byincreasing the diuretic dosage rate provided to the patient at arelatively fast rate, e.g., exponentially during the diuretic dosagedetermining phase (as described elsewhere herein). Simultaneously,hydration fluid can be infused at rates equal to or less than thediuretic dosage rates, to thereby enable net fluid balance over time.The hydration fluid infusion, e.g., during the diuretic dosagedetermining phase, may be done to “jumpstart” the patient's urinationresponse. In some embodiments, the initial hydration fluid infusion cancause the patient to respond to the diuretic more quickly, and so,without being bound by theory, the initial hydration fluid may beinfused in order to inhibit intravascular depletion, as well as inhibitdrops in cardiac output and renal perfusion. As described elsewhereherein, in some embodiments the algorithm may control the hydrationfluid infusion rate to substantially match (e.g., at least 90% or 100%)the urine output rate while administering the initial diuretic dosage(e.g., during the diuretic dosage ramp) for an initial amount (e.g., atleast the initial 150 ml, 200 ml, 250 ml, 300 ml, 400 ml, 500 ml, orwithin a range of 150-500 ml) of urine output or for a first time period(e.g., the first hour, 2 hours, or 3 hours), whichever comes first. Itis noted that the need for initial hydration fluid infusion may bedetermined more by the desire to achieve better patient response to thediuretic, as opposed to decreasing salt concentration of fluid levels,which may be the driving need for hydration fluid infusion in subsequentoperating phases. For example, hydration fluid infusion during the fluidreduction phase or continuous infusion phase may be done to optimize netfluid removal while also avoiding safety risks, e.g., by maintaining asafe blood pressure and sodium level. That is, a goal of infusinghydration fluid is to maximize net fluid removal while avoiding addingtoo much sodium back and/or in any way increasing the likelihood ofcausing a hypotensive state.

As shown in FIG. 9 , the urine rate may be classified into differentregions, including a first region (I), a second region (II), a thirdregion (III), and a fourth region (IV), with each subsequent regioncorresponding to a higher urine output rate 905. The first region (I)can correspond to a urine rate below a first threshold (e.g., 175 ml/hr,225 ml/hr, 275 ml/hr, or within a range of 175-275 ml/hr), the secondregion (II) can correspond to a urine rate between the first thresholdand a second threshold (e.g., 375 ml/hr, 425 ml/hr, 500 ml/hr, or withina range of 375-500 ml/hr), the third region (III) can correspond to aurine rate between the second threshold and a third threshold (e.g., 975ml/hr, 1025 ml/hr, 1100 ml/hr, or within a range of 975-1100 ml/hr), andthe fourth region (IV) can correspond to a urine rate above the thirdthreshold. As shown in FIG. 9 , as the urine rate 905 increases, thehydration rate 910 generally increases as well, but at a rate less thanthat of the urine rate 905. In doing so, the net fluid balance 915decreases (i.e., becomes more negative) and net fluid loss increases.Urine output rate is continuously calculated throughout the treatment sothe algorithm can respond to changes quickly. For example, flow, weight,volume, and/or other characteristics indicative of volumetric ratechange of the urine may be measured every minute, and the urine outputrate 905 can be calculated every minute based on a previous time period(e.g. 5 minutes, 10 minutes, 20 minutes, or within a range of 5-20minutes). Assessing how much hydration fluid to infuse may occur everyminute.

As shown in FIG. 9 , when urine rate 905 is in the first region (I)below the first threshold, the hydration fluid rate 910 may be zero, ora minimum amount (e.g., 10 ml/hr), e.g., to keep the vein pressurizedand open (referred to as a Keep Vein Open (KVO) rate). Since the urineoutput is low in the first region, rehydration is less or not necessary,Also, as a general goal is to maximize net fluid removal, no infusion ofhydration fluid may be provided when the urine rate 905 is in the firstregion (I). As previously described, in some embodiments, the hydrationfluid rate 910 may match the urine rate 905 for a first period of timeor until a minimum amount of hydration fluid is infused.

When the urine rate 905 is in the second region (II), substantially all(e.g., at least 90% or 100%) of the urine volume in the second region(II) (i.e., between the first and second thresholds) is replaced byhydration fluid, e.g., to ensure the kidneys are getting enough fluidand salt, and to inhibit a hypotensive state.

When the urine rate 905 is in the third region (III), substantially all(e.g., at least 90% or 100%) of the urine volume in the second region(II) between the first and second thresholds can be replaced byhydration fluid, and 40%, 45%, 50%, or a range of 40-50% of the urinevolume above in the third region (III) and above the second threshold isreplaced. By only replacing a portion of the urine rate above the secondthreshold, net fluid balance as well as salt concentration can bedecreased. Urine typically has less sodium concentration than blood ornormal saline, which is approximately 154 mmol/L. As such, replacingurine with an equal amount of hydration fluid may result in increasedand undesirable sodium levels. In some embodiments, providing saline orhydration fluid at a rate of more than 50% of the urine rate canincrease the risk of giving them more sodium than they are releasing.Accordingly, limiting the hydration fluid rate to 50% can protectpatients having low sodium urine, while also enabling patients havinghigher sodium urine to experience faster net fluid and sodium removal.Urine output rate in the third region (III) can serve as an indicationthat the kidneys are functioning well and not in a hypotensive state,and so the reduced hydration fluid rate is more acceptable.

When the urine rate 905 is the fourth region (IV), substantially all(e.g., at least 90% or 100%) of the urine volume in the second region(II) between the first and second thresholds can be replaced byhydration fluid, 40%, 45%, 50%, or a range of 40-50% of the urine volumein the third region (III) between the second and third thresholds can bereplaced, and none of the urine volume in the fourth region (IV) abovethe third threshold is replaced. In doing so, the net fluid balance canbe further decreased.

It was previously thought that removing high excess fluid amounts (e.g.,greater than 5 L) within 24 hours with conventional therapy methodswould be dangerous and could cause hypotension. However, embodiments ofthe present technology have shown that even at relatively high urinerates (e.g., at urine rates within the third or fourth regions),removing excess fluid amount (e.g., via infusing hydration fluid at 50%replacement) of at least 5 L per day can be safely done with limited orno risk of kidney failure.

In some embodiments, a net fluid loss limit may be set based on theurine rate at the time and/or region the urine rate is in, with the netfluid loss limit increasing for each subsequent region. For example, thenet fluid loss limit for (i) the first region (I) can be 80 ml/hr, 90ml/hr, 100 ml/hr, or within a range of 80-100 ml/hr, (ii) the secondregion (II) can be 100 ml/hr, 130 ml/hr, 160 ml/hr, or within a range of100-160 ml/hr, (iii) the third region (III) can be 250 ml/hr, 400 ml/hr,500 ml/hr, or within a range of 250-500 ml/hr, and (iv) the fourthregion (IV) can be 500 ml/hr, 750 ml/hr, 900 ml/hr, or within a range of500-1000 ml/hr.

IV. Methods for Causing Net Fluid Loss from a Patient

FIG. 10 is a flow diagram of a method 1000 for causing net fluid lossfrom a patient, in accordance with embodiments of the presenttechnology. The method 1000 can be implemented via a computer, acontroller, and/or in the form of executable tangible, non-transitorycomputer-readable media. For example, the method 1000 can correspond toexecutable instructions that are executed by one of more processors thatare part of a console or associate device.

The method 1000 can include obtaining a urine output rate from a patient(process portion 1002), e.g., by receiving an input from a flow,volumetric, weight, optical or other sensor for determining flow. Theurine rate can be an average rate measured over the previous 5 or 10minutes and be updated on a continuous or recurring basis (e.g., every30 seconds, 1 minutes, 2 minutes, etc.).

The method 1000 can include causing a diuretic to be provided to thepatient at a dosage rate (process portion 1004). The diuretic cancomprise furosemide, bumetanide, ethacrynic acid, torsemide, and/orother diuretics known in the art, and may be part of a solutionincluding saline or other hydration fluid mixed therewith. The diureticcan be provided to the patient as part of a diuretic dosage determiningphase, as described elsewhere herein (e.g., with reference to FIGS.2A-4B). For example, the diuretic can be provided at an initial dosageand then increased in a rapid manner. In some embodiments, the diureticdosage rate can be increased exponentially and/or in a manner thatdoubles the diuretic dosage rate or total diuretic within a period oftime (e.g., 10 minutes, 15 minutes, 20 minutes, or within a range of10-20 minutes).

The method 1000 can include causing a hydration fluid to be provided tothe patient at a hydration rate no more than the urine output rate(process portion 1006). The hydration fluid can comprise saline or otherfluids having sodium. The hydration fluid can be provided to the patientbased on the corresponding urine rate. For example, as describedelsewhere herein, the hydration fluid rate may be determined based onwhether the urine rate is above or below a number of differentthresholds (e.g., the first threshold, second threshold, and thirdthreshold described with reference to FIG. 9 ), with the differencebetween the urine rate and each threshold increasing as the urine rateincreases. In some embodiments, the hydration fluid may substantiallymatch the urine rate for an initial amount (e.g., at least the initial150 ml, 200 ml, or 250 ml) of urine provided to the patient and/or foran initial time period (e.g., the first hour, 2 hours, or 3 hours).

The method 1000 can include adjusting at least one of the dosage rate ofthe diuretic or the hydration rate of the hydration fluid, therebycausing net fluid loss from the patient (process portion 1008). In thisregard, the difference between the diuretic dosage rate and thehydration rate may be increased by increasing the diuretic dosage rate,increasing the diuretic dosage rate relative to the hydration fluid,and/or decreasing the hydration fluid. As described elsewhere, adjustingone or both of the diuretic dosage rate and hydration fluid rate may bedone while also requiring a minimum fluid loss limit.

In some embodiments, adjusting the dosage rate of the diuretic cancomprise ramping or reramping the diuretic dosage. Determining whetherto initiate a reramp can be based upon a set of conditions (e.g., theset of conditions described with reference to process portion 510; FIG.5 ). For example, a trigger for the reramp may require determiningwhether (i) the average urine rate is below a predetermined thresholdrate (e.g., 250 ml/hr, 300 ml/hr, 325 ml/hr, 350 ml/hr, or 400 ml/hr)for a predetermined period of time (e.g., 2 hours, 2.5 hours, or 3hours), and/or (ii) more than a predetermined amount (e.g., 100 ml, 125ml, 150 ml, 175 ml) of debt has accumulated over the predeterminedperiod of time. As previously described, debt can be defined as the areabelow a threshold (e.g., 250 ml/hour, 275 ml/hour, 325 ml/hr, or withina range of 250-325 ml/hr) and above the current urine rate over a givenperiod of time. If one of these conditions is met, a reramp may beinitialized.

The reramp can occur after an initial ramp of the diuretic (e.g., duringthe diuretic dosage determining phase) and in response to the urine ratedropping below a threshold. For example, as described with reference toFIGS. 5 and 6 , if the urine rate (e.g., the average urine rate) isdetermined to be low, based on a set of conditions, the system can beginto reramp the diuretic dosage rate, e.g., after receiving confirmationfrom the patient that it is ok to do so. The reramp can be implementedin a manner similar to the diuretic dosage determining phase, in thatthe diuretic dosage rate is increased rapidly until a period of timeelapses and/or a urine rate of the patient rises above a predeterminedthreshold. For example, in such embodiments, the diuretic dosage isincrementally increased exponentially, such that each diuretic dosagerate is greater than the immediately previous diuretic dosage rate,e.g., by at least 50%, 75%, 100%, or within a range of 50-100%. In suchembodiments, the diuretic dosage rate can effectively double one or moretimes throughout a particular ramp or diuretic dosage determining phase.At such time that the ramp ceases due to the period of time elapsing orthe urine rate rising above the predetermined threshold, the diureticdosage rate can be further adjusted, e.g., by setting the diureticdosage to be a percentage of the total diuretic delivered up to thatpoint. The total amount of diuretic delivered can include that deliveredduring the reramp and, if applicable, any previous ramp that occurred.

The ramp and reramp feature of embodiments of the present technology canbe beneficial to the user and fluid therapy generally, as it allows theurine rate of the patient to increase as quickly as possible, while alsomaintaining safe levels of intravascular volume (e.g., by infusinghydration fluid) so as to minimize the risk of hypotension and drops incardiac output and renal perfusion. Additionally or alternatively, theramp and reramp features, in combination with other features, ofembodiments of the present technology also enable the patient, operator,or system itself to treat patients and relieve them of excess fluidconditions quickly. That is, embodiments of the present technology havebeen shown to remove fluid amounts in excess of 7.5 L over timespans ofless than 24 hours. Moreover, because embodiments of the presenttechnology are configured to rapidly increase a patient's urine rate ina relatively short time period, the system can also automaticallydetermine if the patient is not responding appropriately to a particularfluid therapy. That is, if after providing the diuretic according to theramp or diuretic dosage determining phase, as described herein, thepatient's urine rate does not increase in the manner expected, this mayindicate that the patient is diuretic resistant of that another problemexists requiring further investigation. Accordingly, embodiments of thepresent technology can enable issues such as diuretic resistance to bediscovered and subsequently treated of dealt with in a shorter period oftime than other conventional technologies.

FIG. 11 is a flow diagram of a method 1100 for causing net fluid lossfrom a patient, in accordance with embodiments of the presenttechnology, in accordance with embodiments of the present technology.The method 1100 can be implemented via a computer, a controller, and/orin the form of executable tangible, non-transitory computer-readablemedia. For example, the method 1100 can correspond to executableinstructions that are executed by one of more processors that are partof a console or associate device. The method 1100 can include processportions 1002, 1004, 1006, as described with reference to FIG. 10 .

The method 1100 can include determining whether any one of apredetermined set of conditions is met (process portion 1108), e.g., todetermine whether the urine rate is too high. The set of conditions cancorrespond to those described with reference to FIG. 7 (e.g., processportions 704, 706, 708) and FIG. 8 . For example, the set of conditionscan include determining whether the average urine rate is greater than apredetermined rate for a first period of time (e.g., 2 hours, 3 hours, 4hours, or within a range of 2-4 hours). The predetermined rate can bedependent on whether hydration fluid is being infused to the patient. Ifhydration fluid is being infused to the patient, the predetermined ratecan be 900 ml/hr, 950 ml/hr, 1025 ml/h, 1100 ml/hr, or within a range of900-1100 ml/hr. If no hydration fluid is being infused to the patient,the predetermined rate can be 400 ml/hr, 450 ml/hr, 525 ml/hr, 600ml/hr, or within a range of 400-600 ml/hr. The set of conditions canfurther include determining whether an average rate of change of theurine rate (i.e., a slope) is greater than a predetermined rate ofchange (e.g., 30 ml/hr², 40 ml/hr², 50 ml/hr², 60 ml/hr², 70 ml/hr², orwithin a range of 30-70 ml/hr²) for a second period of time (e.g., 1hour, 2 hours, 3 hours, or within a range of 1-3 hours). The set ofconditions can further include determining whether the diuretic dosagerate is greater than a predetermined dosage rate (e.g., 8 mg/hr, 10mg/hr, 12 mg/hr, or within a range of 8-12 mg/hr).

The method 1100 can include, if at least two of the set of conditions ismet, decreasing the dosage rate of the diuretic by a predeterminedamount. That is, if two or three of the following conditions are met,the dosage rate may be decreased: (i) the average urine rate is greaterthan the predetermined rate for the first period of time, (ii) theaverage rate of change of the urine rate is greater than thepredetermined rate of change, and (iii) the diuretic dosage rate isgreater than the predetermined dosage rate. In some embodiments, eachone of the set of conditions must be met in order to decrease the dosagerate of the diuretic by a predetermined amount. By requiring all or amajority of the set of conditions to be met, the system avoidsunnecessarily decreasing the diuretic dosage rate, thereby allowingurine rates to remain high and preventing fluid therapy from beingunnecessarily interrupted. For example, whereas other methodologies mayinterrupt fluid therapy and decrease the diuretic dosage rate when theurine rate is just too high, embodiments of the present technology mayonly decrease the dosage rate (per process portion 1110) when the urinerate is both high and increasing. Stated differently, such a methodologycan prevent the diuretic dosage rate from being unnecessarily decreasedwhen urine rates are high (e.g., above the predetermined rate)temporarily but are trending downward to eventually be below thepredetermined rate. In doing so, embodiments of the present technologycan also prevent or inhibit over-diuresis, excess fluid loss and/orelectrolyte loss, as well limit unnecessary exposure of the patient toadditional diuretic. Additionally or alternatively, down-titrating thediuretic dosage rate, as opposed to ceasing the diuretic dosage, isbeneficial, as fluid therapy can be continued (albeit at lower urinerates) without the need for a complete restart. This allows net fluidbalance to continue to increase even during the down-titration event, asopposed to ceasing the fluid therapy and thereby halting net fluid lossincreases. Additionally or alternatively, by mitigating the potentialhazard of diuretic overshooting (e.g., when ramping the diuretic duringthe dosage determining phase) and limiting overexposure of the patientto the diuretic, there may be additional regulatory benefits to havingthe down-titration methodology.

Decreasing the dosage rate of the diuretic by a predetermined amount cancorrespond to the down-titration methodology described elsewhere hereinwith reference to FIG. 7 (e.g., process portion 710, 712, 714, 716, 720)and FIG. 8 . For example, decreasing the dosage rate of the diuretic cancomprise decreasing the diuretic dosage by a predetermined percentage(e.g., 20%, 25%, 30%, or within a range of 20-30%) for a period of time(e.g., 2 hours, 3, hours, 4 hours, or within a range of 2-4 hours). Insome embodiments, after decreasing the diuretic dosage and once theperiod of time has elapsed, the counters associated with the set ofconditions may be reset. In such embodiments, the diuretic dosage canremain at the down-titrated levels or be adjusted based on thesubsequent operating phase of therapy. If the third period of time hasnot elapsed and the average urine rate drops below a down-titrationthreshold, the diuretic dosage rate can be adjusted (e.g., increased)based on the elapsed time at that moment. In some embodiments, thepredetermined percentage that the diuretic dosage rate is decreased byis reduced by the fraction of the period of time that has elapsed. Forexample, assuming a predetermined percentage of 25% and a period of timeof 3 hours, if the diuretic dosage drops below the down-titrationthreshold 90 minutes after the down-titration began, the diuretic dosagewould then be increased to be only half of the predetermined percentage,or 12.5%. After the diuretic dosage is adjusted per process portion1110, the counters associated with the set of conditions may be reset,as previously described.

V. Example: Fluid Overload Therapy with Diuretics and Hydration Fluid

The following example is included to further describe some aspects ofthe present technology, and should not be used to limit the scope of theinvention.

Clinical data associated with embodiments of the present technology wereobtained from patient tests conducted at the Tbilisi Heart and VascularCenter in Tbilisi, Ga. 15 patients underwent fluid therapy in whichdiuretic(s) and hydration fluid were administered via the ReprieveCardiovascular™ Second Generation System according to the methodsdescribed herein (“treatment group”). As described below, data obtainedfrom the tests indicate that the net fluid loss and net sodium losslevels achieved represent a significant improvement over conventionalmethods for treating fluid overload conditions, and generally indicatethat embodiments of the present technology produce improved diuresis andrenal safety.

Table 1 below indicates total urine output, net fluid loss (notincluding intake fluid), net fluid loss (including intake fluid), netsodium balance, and average diuretic (Lasix) dosage rate for eachpatient in the treatment group, as measured across a therapy timespan.As shown in Table 1, the average net fluid loss (not including oralfluid intake) for patients in the treatment group was nearly 7 liters(L) over an average therapy timespan of 31 hours. When normalized over a24-hour period for each patient, average net fluid loss wasapproximately 5.4 L. Compared to patients undergoing conventional fluidtherapy treatment (i.e., administered diuretic with no replacementhydration fluid) (“control group”), which achieved an average net fluidloss of 1.75 L over a normalized 24-hour period, the treatment groupshowed over 200% increase in net fluid loss. Additionally, the averagetherapy timespan for the treatment group was 31 hours, whereas theaverage therapy timespan for standard of care therapy in the literatureis approximately 5 days. Accordingly, the combined diuretic andhydration fluid treatment was able to achieve significantly more netfluid loss and decreased overall therapy time relative to conventionaltreatments. During the treatment, the patients in the treatment groupalso showed an average weight loss of 6.8 kilograms (kg) at the time ofpatient discharge, and an average loss of 5.7 kg after 30 days. Over the30 days, none of the patients in the treatment group regained the weightthat lost during therapy or were readmitted for additional treatment.

TABLE 1 Clinical data for treatment group patients Net Fluid Net FluidLoss (not Loss Total including (including Therapy Avg. Urine oral fluidoral fluid Timespan Lasix/Hr Patient # (ml) intake) (ml) intake) (ml)(hh:mm) (mg) 1 9,162 −4,704 −3,844 23:49 13 2 14,158 −6,001 −4,868 30:3444 3 11,456 −4,590 −4,247 24:51 10 4 6,329 −2,993 −2,232 21:03 36 519,728 −11,913 −10,787 53:44 82 6 3,726 −2,003 −1,021 26:06 44 7 12,966−8,306 −6,276 45:55 79 8 12,179 −6,941 −5,625 27:01 — 9 6,496 −3,953−3,636 21:10 25 10 20,184 −12,269 −10,299 50:43 15 11 8,328 −4,364−3,724 19:06 58 12 17,784 −9,995 −9,156 29:07 27 13 14,629 −7,888 −6,58333:40 29 14 12,930 −7,018 −6,186 21:34 30 15 21,155 −11,333 −10,30140:08  7 Average 12,744 −6,948 −5,919 31 39

As also shown in Table 1, the average diuretic dosage rate was nearly 40mg/hr, which corresponds to a daily dose of nearly 950 mg. This diureticdosage rate and dose were significantly higher than corresponding dosagerate and dose for the conventional treatment methods, and thuscontributed to the relative increased treatment efficacy of theembodiments of the present technology.

As also shown in Table 1, the average net sodium balance for allpatients in the treatment group decreased by nearly 800 millimoles(mmol) over the therapy timespan. When normalized over a 24-hour period,the average and median net sodium balance was −14 grams (g) and −15 grespectively. Relative to conventional treatment methods, which showed amedian net sodium balance of −3.63 g over a normalized 24-hour period,this represents an improvement of over 11 g or 300%.

Estimated glomerular filtration rate (eGFR) is a measure of kidneyfunction and stage of kidney disease, and is based on patient factorsincluding blood creatinine and a patient's age, body size, and gender.The patients in the treatment group showed an average increase increatinine of 0.11 mg/dL (deciliter) and only a modest average decreaseof 1.6 eGFR over a 30-day span. Such modest changes in eGFR, especiallygiven the amount and rate of net fluid loss, indicate the fluid therapywas generally well tolerated by the patients and kidney function aftertherapy was largely maintained at pre-treatment levels.

Blood pressure measurements of the patients in the treatment group serveas another indication that the fluid therapy was well received by thepatients. For example, the average mean arterial pressure (MAP) ofpatients dropped from 90.1 mmHg to 88.2 mmHg at the time of patientdischarge, and then to 87.2 mmHg after 30 days. Additionally, averagesystolic pressure of the patients dropped from 121 mmHg to 119 mmHg atthe time of patient discharge, and then to 117 mmHg after 30 days. Suchmodest changes in MAP and systolic pressure, especially given the amountand rate of net fluid loss, indicate the fluid therapy was generallywell tolerated by the patients.

VI. Exemplary Functional Requirements of Embodiments of the PresentTechnology User Interface Displays

The software shall display the Urine Production Rate reported by theurine monitoring device.The software shall display the Net Target, defined as the (Desired FluidBalance)*(−1)+(Urine BufferRange) (Note: Default Desired Fluid Balance is −225 and default UrineBuffer Range is 100, thus default Net Target is 325)The software shall display the total urine over the previous hour (“LastHour Urine”)The software shall display the total urine over the previous 2-hours(“Last 2-Hour Urine”)The software shall display the total urine over the previous 3-hours(“Last 3-Hour Urine”)The software shall display the total “Debt”, defined as the area belowthe “Net Target” and above the “Urine Production Rate” over the previousthree hours. If the urine production rate is above the “Net Target”,“debt” is not added or removed.The software shall display the Average Urine Rate over the previoushour.The software shall display the time in the current mode.The software shall display the total diuretic dose during the previousRamp.The software shall display the total urine measured by the urinemonitoring device during the previous Ramp.The software shall display the time the previous ramp exceeded thetarget urine rate (Note: default target urine rate is 525 ml/hr).The software shall display the total diuretic infused since the start oftherapy.The software shall display the total diuretic infused during theprevious 24 hours.The software shall display the current diuretic infusion rate.The software shall display the total saline infused since the start oftherapy, as reported by the hydration fluid infusing device.The software shall display the total urine measured since the start oftherapy, as reported by the urine monitoring device.The software shall display the measured net fluid balance (“RemovedVolume” since the start of therapy, based on a difference between totalurine output and total hydration fluid infused.The software shall display the current fluid balance target.The software shall plot the urine rate and may display the urine rate,such as an average rate over one or more periods of time, such as 15minutes, 1 hour and/or three hours. The software shall plot the diureticinfusion rate on the same plot as the urine rate.The software shall provide the user the ability to adjust the time scaleand the y-axis of the urine plot.The software shall indicate that the diuretic infusing device, urinemonitor device and/or the hydration fluid source are connected to theconsole(s) housing the computer control system.The software shall indicate that the diuretic dispensing device, e.g., ainfusion syringe for dispensing a diuretic, is connected.

Keys

The software shall provide a button to allow the user to start therapy.The software shall provide a button to allow the user to stop therapy.The software shall provide a button to allow the user to pause infusion.The software shall provide a button to allow the user to stop the rampand go to continuous infusion.The software shall provide a button to allow the user to enable manualcontrol of the diuretic infusion rate.The software shall provide a control to allow the user to adjust thediuretic pump rate in milliliters/hour.The software shall provide a means to allow the user to confirm errormessages.The software shall provide a means to allow the user to reset a serialport for the syringe infusion system.The software shall provide a means to allow the user to reset one ormore serial ports on the console(s) housing the computer system, whereinthe ports are to connected to one or more of the urine monitoringdevice, the diuretic dispensing device and the hydration fluid source ordispensing device.The software shall provide a means to allow the user to initiate Rampmode.The software shall provide a means to allow the user to Download anevent log from the computer system.

Settings

The software shall allow the user to set the following parameters:Urine Buffer Range (ml/hr)—the rate above the “Desired FluidBalance”*(−1) used as a target. Default value: 100 ml/hr.Urine Rate Target (ml/hr)—urine rate target during the ramp phase.Default value: 525 ml/hr.Debt Threshold (ml/hr)—urine rate below which debt is calculated.Default value: 325 ml/hr.

Mode Control Ramp Mode:

The software shall provide a Ramp mode, that begins when the userinitiates Diuretic Management.If NO file input is selected by the user upon initiation of the diureticinfusion, the IV Infusion of the diuretic shall exponentially rampfollowing a log base 2 curve from 0 to the max rate required to infuse200 mg of Furosemide if given for 60 minutes.If a file input is selected by the user, the IV infusion shall followthe specified profile.The IV infusion described in shall be stopped either:a) when 60 minutes elapse from the start of ramp without reaching thetarget urine rate

OR

b) when the console measured Urine Production Rate is higher or equal tothe user adjustable target urine rate (default 525 ml/h). The softwareshall then wait 10 minutes and monitor the urine output rate. Duringthis time, the software shall set the diuretic pump rate to 20% of thecurrently delivered dose. If the urine output rate remains above 525ml/hr, the software shall enter Continuous Infusion mode, if the urinerate is now below 525 ml/hr, the ramp shall resume for at least 5minutes.

OR

c) per user requestWhen the Ramp completes, the software shall enter continuous infusion.

Pause:

During the ramp phase, the user shall be provided with the option topause the IV infusion. Upon requesting the IV infusion to resume the IVinfusion shall start at the rate at which it was paused and follow theselected IV infusion pattern for the time remaining until the conclusionof 60 minutes.

Continuous Infusion:

Once the ramp completes, the system shall continue to administer acontinuous diuretic IV infusion rate based on the formula below:

Infusion rate(mg/hour)=0.2*(total amount of diuretic infused during theramp phase in mg that corresponds with the minute of the ramp that wascompleted)

If the infusion rate calculated in the previous step is less than 4mg/hr, it will be set to 4 mg/hr.During continuous infusion mode, the system shall monitor the patient'surine output to determine if Ramp mode or Downtitrate mode criteria havebeen met.If the urine output is consistently above 625 ml/hr for 3 hours, and theslope of the urine rate over the previous 2 hours predicts that theurine the urine output will be above 625 ml/hr in three hours, thesoftware shall enter Downtitrate mode.If the average urine output is below the Urine Buffer Range+Net Target(default 325 ml/hr) for three hours, or if the accumulated debt over theprevious 3 hours exceeds 150 ml, the software shall re-enter ramp mode.Debt shall be defined as the area below the Debt Threshold (defaultvalue 325 ml/hr) and above the urine rate when the urine rate is belowthe debt threshold. Ramp mode shall resume at the minute in the rampphase that corresponds with the current infusion rate (RampTotal=infusion rate/0.2)The Ramp mode shall not be entered if the urine output in the previous15 minutes is less than 25 ml (100 ml/hr).The Ramp mode shall not be entered if the current infusion ratecorresponds with 55 minutes of the ramp or greater.

Downtitrate:

If Downtitrate mode is initiated, the software shall set the pump speedto 0.4 ml/hr for up to 50 minutes.If those 50 minutes complete without the urine rate dropping below 525ml/hr, the software shall resume the continuous infusion at 75% of therate prior to the initiation of down titration (a 25% reduction in therate).If during those 50 minutes, the urine output drops below 525 ml/hr, thesoftware shall resume infusion at a rate calculated as follows:

New infusion rate=previous infusion rate *(1−0.25*(minute urine ratedropped below 525)/50)

Re-Ramp:

The software shall provide a means to allow the user to re-initiate Rampmode.When the Ramp restarts, it shall continue for at least 5 minutes.When the Ramp restarts, it shall continue restart at the minute of theramp corresponding to the current continuous infusion rate (as in, itshould restart at the minute in the ramp where the ramp ending wouldresult in the continuous infusion rate currently set).The ramp shall continue the exponential ramp from the initial ramp.When the urine production rate reaches the target urine rate (525ml/hr), the software shall switch to the continuous infusion rate thatcorresponds to the current minute of the total ramp (i.e. if the re-rampstarts at minute 25, and runs for 10 minutes, the continuous infusionrate shall be set to the same rate as it would have had the initial ramprun for 35 minutes).If the ramp is Restarted, the debt shall be reset to 0 and the 3 houraverage urine rate timer shall be reset.

Manual:

The software shall provide a mode to allow the user to set the diureticinfusion rate.The units of diuretic infusion setting shall be in ml/hr.The increments of the diuretic infusion setting shall be 0.1 ml/hrThe minimum value shall be 0.4 ml/hr.The maximum value shall be 4.0 ml/hr.The user shall have the option of enabling and disabling the diureticcontrol algorithm to operate while in manual mode.

Off:

The software shall provide an “off” mode, during which time Diureticmanagement is stopped, and the diuretic dispensing device, e.g., Gaseby™infusion syringe, is stopped.When the user turns the Diuretic management back on, control shallresume where it was prior to entry to “Off” mode.

Monitoring & Protection Functions

The software shall inform the user if there is an alarm on the diureticdispensing device, e.g., Gaseby™ infusion syringe.The software shall inform the user if the diuretic dispensing device,e.g., Gaseby™ infusion syringe pump, is disconnected.The software shall inform the user if the system is not in Run mode.The software shall inform the user if the urine rate over the previous15 minutes is below the limit to enableWhen the diuretic dispensing device, e.g., Gaseby™ infusion syringepump, goes into alarm mode, the application shall wait for the alarms tobe manually cleared and consequently set the pump infusion rate to theprevious value and mode.When a different diuretic dispensing device, e.g., Gaseby™ infusionsyringe pump, infusion rate is detected than the one requested by theapplication, the application shall stop the pump and notify the user.Exemplary software code for the hydration fluid control component of thealgorithm is as follows:

static void calcNetGain( float period_urine_delta ) {  float setting=0.0;  float netGain_mlphr;   //float maxFluidLossRate;  //floatexcessUrineOutput; //urine output over and above the max loss rate, inml/hr   float pMatchSetting;  //float urine_rate_exceeding_net_gain; float percent_match_adjustment_to_target;  float fullMatchLimit,urine_rate_exceeding_full_match_limit;  float fullMatchRange ; //  floatinitalBalanceVolume;  //float kvo_setting;  floatdesired_fluid_loss_rate;  float fluid_match_rate;   netGain_mlphr =getUserSetting( DESIRED_BALANCE_SETTING );   pMatchSetting =getUserSetting( PERCENT_MATCH_SETTING );    fullMatchRange =getUserSetting( PCT100_MATCH_RANGE_SETTING );    initalBalanceVolume =getUserSetting( INITIAL_FLUID_MATCH_SETTING );    maxHourlyInfusion =getUserSetting( HOURLY_INFUSION_LIMIT_SETTING )    if ( netGain_mlphr >=0 )    {    setting = ( float ) ( ( ( double ) netGain_mlphr * ( double) FlowControlInterval ) / 3600.0 ); //convert from ml/hr to ml/s    if ((pMatchSetting >= 0) && (pMatchSetting < 100)) //apply percent match ifit's set and negative net gain is not    {     setting−=period_urine_delta * ( (100-pMatchSetting) / 100 );    }   fluid_match_rate = LightUrineRate + (setting)*3600.0/( double)FlowControlInterval;    if ( fluid_match_rate > maxHourlyInfusion)//ifthe current setting exceeds the current max hourly rate, clip it to themax hourly rate    {     desired_fluid_loss_rate =(−1.0)*(LightUrineRate − maxHourlyInfusion); //rate of fluid loss inml/hr     setting = ((desired_fluid_loss_rate* ( double )FlowControlInterval) / 3600.0 ); //convert from ml/hr to ml/s    }    }   else if( (control_data.accumulated_urine_weight > initalBalanceVolume) ∥ ( GetRunModeTime( ) > 3600 ) ) //only use negative net gain if 500ml volume reached or 60 minutes    {    fullMatchLimit = abs(netGain_mlphr ) + fullMatchRange; // calculate rate where percent matchbegins    if ( LightUrineRate > abs( netGain_mlphr ) ) //urine rate ifabove the max net gain    {     if ( LightUrineRate < fullMatchLimit )//if in full match range, take off net gain, but nothing else     {     setting = ( float ) ( ( ( double ) ( netGain_mlphr ) * ( double )FlowControlInterval ) / 3600.0 ); //convert from ml/hr to ml/s     }    else     {      urine_rate_exceeding_full_match_limit =LightUrineRate − fullMatchLimit; //calculate the amount of urineexceeding full match limit      percent_match_adjustment_to_target =urine_rate_exceeding_full_match_limit * ( (100− pMatchSetting) / 100 );     setting = ( float ) ( ( ( double ) ( netGain_mlphr −percent_match_adjustment_to_target ) * ( double ) FlowControlInterval )/ 3600.0 ); //convert from ml/hr to ml/s     }     fluid_match_rate =LightUrineRate + (setting)*3600.0/( double )FlowControlInterval;//setting is negative− calculate rate of replacement with currentsetting     if ( fluid_match_rate > maxHourlyInfusion)//if the currentsetting exceeds the current max hourly rate, clip it to the max hourlyrate     {      desired_fluid_loss_rate = (−1.0)*(LightUrineRate −maxHourlyInfusion); //rate of fluid loss in ml/hr      setting =((desired_fluid_loss_rate* ( double ) FlowControlInterval ) / 3600.0 );//convert from ml/hr to ml/s     }    }    else    {     //if urine rateis below desired fluid balance, take the urine rate off of the target    setting = −( ( ( double ) LightUrineRate * ( double )FlowControlInterval ) / 3600.0 ); //convert from ml/hr to ml/s    }   // increment get gain by the user setting for this interval   }  control_data.net_gain_target += setting; } // end func calcNetGain( )

VII. Conclusion

It will be apparent to those having skill in the art that changes may bemade to the details of the above-described embodiments without departingfrom the underlying principles of the present technology. In some cases,well known structures and functions have not been shown or described indetail to avoid unnecessarily obscuring the description of theembodiments of the present technology. Although steps of methods may bepresented herein in a particular order, alternative embodiments mayperform the steps in a different order. Similarly, certain aspects ofthe present technology disclosed in the context of particularembodiments can be combined or eliminated in other embodiments.Furthermore, while advantages associated with certain embodiments of thepresent technology may have been disclosed in the context of thoseembodiments, other embodiments can also exhibit such advantages, and notall embodiments need necessarily exhibit such advantages or otheradvantages disclosed herein to fall within the scope of the technology.Accordingly, the disclosure and associated technology can encompassother embodiments not expressly shown or described herein, and theinvention is not limited except as by the appended claims.

Throughout this disclosure, the singular terms “a,” “an,” and “the”include plural referents unless the context clearly indicates otherwise.Similarly, unless the word “or” is expressly limited to mean only asingle item exclusive from the other items in reference to a list of twoor more items, then the use of “or” in such a list is to be interpretedas including (a) any single item in the list, (b) all of the items inthe list, or (c) any combination of the items in the list. Additionally,the term “comprising,” “including,” and “having” should be interpretedto mean including at least the recited feature(s) such that any greaternumber of the same feature and/or additional types of other features arenot precluded.

Reference herein to “one embodiment,” “an embodiment,” “someembodiments” or similar formulations means that a particular feature,structure, operation, or characteristic described in connection with theembodiment can be included in at least one embodiment of the presenttechnology. Thus, the appearances of such phrases or formulations hereinare not necessarily all referring to the same embodiment. Furthermore,various particular features, structures, operations, or characteristicsmay be combined in any suitable manner in one or more embodiments.

Unless otherwise indicated, all numbers expressing concentrations, shearstrength, and other numerical values used in the specification andclaims, are to be understood as being modified in all instances by theterm “about.” Accordingly, unless indicated to the contrary, thenumerical parameters set forth in the following specification andattached claims are approximations that may vary depending upon thedesired properties sought to be obtained by the present technology. Atthe very least, and not as an attempt to limit the application of thedoctrine of equivalents to the scope of the claims, each numericalparameter should at least be construed in light of the number ofreported significant digits and by applying ordinary roundingtechniques. Additionally, all ranges disclosed herein are to beunderstood to encompass any and all subranges subsumed therein. Forexample, a range of “1 to 10” includes any and all subranges between(and including) the minimum value of 1 and the maximum value of 10,i.e., any and all subranges having a minimum value of equal to orgreater than 1 and a maximum value of equal to or less than 10, e.g.,5.5 to 10.

The disclosure set forth above is not to be interpreted as reflecting anintention that any claim requires more features than those expresslyrecited in that claim. Rather, as the following claims reflect,inventive aspects lie in a combination of fewer than all features of anysingle foregoing disclosed embodiment. Thus, the claims following thisDetailed Description are hereby expressly incorporated into thisDetailed Description, with each claim standing on its own as a separateembodiment. This disclosure includes all permutations of the independentclaims with their dependent claims.

The present technology is illustrated, for example, according to variousaspects described below. Various examples of aspects of the presenttechnology are described as numbered examples (1, 2, 3, etc.) forconvenience. These are provided as examples and do not limit the presenttechnology. It is noted that any of the dependent examples may becombined in any combination, and placed into a respective independentexample. The other examples can be presented in a similar manner.

1. A system for removing fluid from a patient, comprising:

-   -   a console housing a computer controller;    -   a urine output device for measuring a rate or volume of urine        production of the patient;    -   a first infusion pump configured to pump a hydration fluid into        the patient; and    -   a second infusion pump configured to pump a diuretic medication        into the patient;    -   wherein the controller is configured to:        -   receive urine output data from urine output device;        -   control the first infusion pump to deliver to the patient a            first desired infusion rate of the hydration fluid while            simultaneously controlling the second infusion pump to            progressively increase a dosage of the diuretic medication;        -   determine a second desired infusion rate of the hydration            fluid, lower than the first desired infusion rate, wherein            the second desired infusion rate is dependent on the rate            and/or the volume of urine production; and        -   control the first infusion pump to deliver the second            desired infusion rate of the hydration fluid while            simultaneously controlling the second infusion pump to            infuse a substantially constant dosage of the diuretic            medication.

2. The system of clause 1, wherein the controller is further configuredto progressively increase the dosage of the diuretic medication inperiodic steps, wherein each step is a greater dosage increase than aprior step.

3. The system of clause 1 or 2, wherein the controller is furtherconfigured to progressively increase the dosage of the diureticmedication in accordance with a linear mathematical function.

4. The system of clause 1 or 2, wherein the controller is furtherconfigured to progressively increase the dosage of the diureticmedication in accordance with an exponential mathematical function.

5. The system of clause 4, wherein the mathematical function is a firstorder exponential function.

6. The system of any of the preceding clauses, wherein the controller isfurther configured to determine the constant dosage of the diureticmedication based on a total amount of the diuretic medication givenwhile controlling the second infusion pump to progressively increase thedosage of the diuretic medication.

7. A system configured to administer a diuretic and a hydration fluid toa patient, comprising:

-   -   a console housing a computer controller;    -   a urine output device for measuring a rate or volume of urine        production of the patient;    -   a first infusion pump configured to pump a hydration fluid into        the patient;    -   a second infusion pump configured to pump a diuretic medication        into the patient;    -   wherein the controller is configured to:        -   control the second infusion pump to infuse a diuretic into            the patient,        -   control the first infusion pump to pump a hydration fluid            containing sodium chloride into the patient, and        -   monitor urine output by the patient,        -   wherein the control of the first infusion pump includes            automatically adjusting a rate of the hydration fluid            infused into the patient in response to changes in the urine            output by the patient.

8. The system of clause 7, wherein the automatic adjustment of the rateof the hydration fluid includes adjusting the rate of the hydrationfluid to substantially match the urine output while the urine output isbelow a first threshold, and to be less than the urine output while theurine output is above the first threshold.

9. The system of clause 8, wherein the first threshold is in at leastone range of 350 ml/hour to 550 ml/hour, 375 ml/hour to 475 ml/hr, 400ml/hr to 450 ml/hr or within 5% of 425 ml/hour.

10. The system of clause 8 or 9, wherein the automatic adjustment of thehydration fluid includes setting the hydration fluid to a fraction of acurrent rate of urine output while the urine output is above the firstthreshold, wherein the fraction is in a range of 70% to 30%, 60% to 40%,or 45% to 55% of the current rate of the urine output.

11. The system of any of clauses 7 to 10, wherein the automaticadjustment of the rate of the hydration fluid includes adjusting therate of the hydration fluid to substantially a constant hydration fluidrate while the urine output exceeds a second threshold.

12. The system of clause 10 wherein the second threshold is above atleast one of 800 ml/hour, 900 ml/hour, 1000 ml/hour, 1025 ml/hour, 1100ml/hour, or 1200 ml/hour.

13. The system of any of clauses 7 to 12, further comprisingautomatically adjusting a rate of the infusion of the diuretic into thepatient during at least one period while the urine output is below athird threshold.

14. A method to treat a patient suffering from fluid overload,comprising:

-   -   causing a diuretic to be administered to the patient to increase        urine output of the patient;    -   determining urine output by the patient while causing the        diuretic to be administered;    -   infusing a hydration fluid into the patient; and    -   automatically adjusting a rate of the hydration fluid infused        into the patient to achieve a desired net fluid loss in the        patient.

15. The method of clause 14, wherein the automatic adjustment of therate of the hydration fluid is calculated based on a difference betweenthe urine output and the desired net fluid loss.

16. The method of clause 14 or 15, wherein the automatic adjustment ofthe rate of the hydration fluid is calculated based on a current rateincrease of the urine output.

17. The method of any clauses 14 to 16, wherein the automatic adjustmentof the rate of the hydration fluid reduces a rate or rate of increase ofthe hydration fluid in response to the urine output exceeding a firstthreshold output.

18. The method of clause 16, wherein the first threshold output is arate of urine output.

19. The method of any of clauses 14 to 18, wherein the automaticadjustment of the rate of the hydration fluid includes increasing therate of the hydration fluid to a rate within ten percent (10%) of acurrent rate of urine output, until the current rate of urine outputreaches a first threshold output.

20. The method of clause 19, wherein the first threshold output is aurine output rate in a range of 200 ml/hr to 240 ml/hr.

21. The method of any of clauses 14 to 20, further comprising limiting arate of the hydration fluid infusion to a maximum limit for thehydration fluid while a current urine output rate is above a secondthreshold is above 500 ml/hr, above 700 ml/hr, or above 1020 ml/hr.

22. The method of any of clauses 14 to 21, further comprising stoppingthe method when the net fluid loss reaches a desired amount for the netfluid loss, such as 5 liters, 8 liters or 10 liters.

23. The method of any of clauses 14 to 22, further comprisingautomatically adjusting the diuretic administered to the patient basedon the urine output.

24. The method of clause 23, wherein the automatic adjustment of thediuretic includes increasing a rate of the diuretic being administereduntil the urine output reaches a desired minimum urine value.

25. The method of clause 24, wherein the minimum urine value is aminimum urine output rate.

26. The method of any of clauses 23 to 25, wherein the step of adjustingthe diuretic includes automatically increasing the diuretic level atintervals of five minutes or less until the urine output reaches thedesired minimum urine value.

27. The method of clause 26, wherein at least one of the increases inthe diuretic level is a greater increase than the immediately priorincrease.

28. The method of clauses 26 or 27, wherein each of the increases in thediuretic level is greater than the increase of the immediately priorincrease.

29. The method of any of clauses 14 to 28, wherein the automaticadjustment of the diuretic includes:

calculating a reduced rate for the diuretic in response to the urineoutput reaching the desired minimum urine value or rate, wherein thereduced rate is below and based on a value of the diuretic administeredwhen the urine output reached the desired minimum urine value or rate,and administering the diuretic at the reduce rate for a period of atleast one hour.

30. A fluid management system, comprising:

-   -   a hydration fluid pump configured to pump a hydration fluid into        a patient;    -   a diuretic pump configured to pump a diuretic into the patient;    -   a measurement device configured to measure urine output of the        patient;    -   a computer configured to:        -   determine an amount or rate of urine output of the patient;        -   automatically inject a diuretic to the patient by            controlling the diuretic pump to deliver the diuretic at a            dosage rate determined by the computer;        -   automatically infuse an amount or rate of a hydration fluid            into the patient by controlling the hydration fluid pump;            and        -   automatically adjust the rate or the amount of the hydration            fluid infused into the patient to achieve a desired amount            or rate of net fluid loss in the patient.

31. The fluid management system of clause 30, wherein the computer isconfigured to determine the automatic adjustment of the amount or rateof the hydration fluid based on a difference between the respectiveamount or rate of urine output and the desired net fluid loss.

32. The fluid management system of clause 30 or 31, wherein theautomatic adjustment of the rate of the hydration fluid is calculatedbased on a current rate increase of the urine output.

33. The fluid management system of any of clauses 30 to 32, wherein theautomatic adjustment of the rate of the hydration fluid reduces a rateincrease of the hydration fluid in response to the urine outputexceeding a first threshold output.

34. The fluid management system of any of clauses 30 to 33, wherein thefirst threshold output is a rate of urine output.

35. The fluid management system of any of clauses 30 to 34, wherein theautomatic adjustment of the rate of the hydration fluid includesincreasing the rate of the hydration fluid to a rate within ten percent(10%) of a current rate of urine output, until the current rate of urineoutput reaches a first threshold output.

36. The fluid management system of any of clauses 30 to 35, wherein thefirst threshold output is a urine output rate in a range of 200 ml/hr to240 ml/hr.

37. The fluid management system of any of clauses 30 to 36, furthercomprising limiting a rate of the hydration fluid infusion to a maximumlimit for the hydration fluid while a current urine output rate is abovea second threshold is above 500 ml/hr, above 700 ml/hr, or above 1020ml/hr.

38. The fluid management system of any of clause 37, wherein thecomputer is further configured to maintain the rate of the hydrationfluid infusion at the maximum limit while the urine output exceeds amaximum threshold urine output rate.

39. The fluid management system of any of clauses 30 to 38, furthercomprising ceasing to automatically inject the diuretic when the netfluid loss reaches a desired amount for the net fluid loss, such as 5liters, 8 liters or 10 liters.

40. The fluid management system of any of clauses 30 to 39, wherein thecomputer is further configured to stop the administration of thediuretic when the fluid loss reaches a desired amount for the net fluidloss.

41. The fluid management system of any of clauses 30 to 40, wherein thecomputer is configured to automatically adjust the diuretic administeredto the patient based on the urine output.

42. The fluid management system of any of clauses 30 to 41, wherein theautomatic adjustment of the diuretic includes increasing a rate of thediuretic being administered until the urine output reaches a desiredminimum urine value.

43. The fluid management system of any of clauses 30 to 42, wherein theminimum urine value is a minimum urine output rate.

44. The fluid management system of any of clauses 30 to 43, wherein theadjustment of the diuretic includes automatically increasing thediuretic level at intervals of five minutes or less until the urineoutput reaches the desired minimum urine value.

45. The fluid management system of clause 44, wherein at least one ofthe increases in the diuretic level is a greater increase than theimmediately prior increase.

46. The fluid management system of clause 44 or 45, wherein each of theincreases in the diuretic level is greater than the increase of theimmediately prior increase.

47. The fluid management system of any of clauses 30 to 46, wherein theautomatic adjustment of the diuretic includes:

-   -   calculating a reduced rate for the diuretic in response to the        urine output reaching the desired minimum urine value or rate,        wherein the reduced rate is below and based on a value of the        diuretic administered when the urine output reached the desired        minimum urine value or rate, and    -   administering the diuretic at the reduce rate for a period of at        least one hour.

48. A method for providing fluid therapy, the method comprising:

-   -   obtaining a urine output rate from a patient;    -   causing a diuretic to be provided to the patient at a dosage        rate;    -   causing a hydration fluid to be provided to the patient at a        hydration rate no more than the urine output; and    -   adjusting at least one of the dosage rate of the diuretic or the        hydration rate of the hydration fluid, thereby causing net fluid        loss from the patient.

49. The method of any one of the clauses herein, wherein adjusting thedosage rate of the diuretic comprises increasing the dosage rate until(i) a predetermined period of time has elapsed, (ii) the urine outputrate is above a first predetermined threshold, (iii) a total amount ofthe diuretic provided is above a second predetermined threshold, and/or(iv) the dosage rate is above a third predetermined threshold.

50. The method of clause 49, wherein the first predetermined thresholdis at least 150 ml/hour, 200 ml/hour, 250 ml/hour, 300 ml/hour, 350ml/hour, 400 ml/hour, 450 ml/hour, 500 ml/hour, or 525 ml/hour.

51. The method of any one of clauses 49 or 50, wherein the secondpredetermined threshold is at least 100 mg, 150 mg, 200 mg, or 250 mg.

52. The method of any one of clauses 49-51, wherein the thirdpredetermined threshold is at least 20 mg/hour, 30 mg/hour, 40 mg/hour,or 50 mg/hour.

53. The method of any one of clauses 49-52, wherein the predeterminedperiod of time is at least 20 minutes, 30 minutes, 40 minutes, or 60minutes.

54. The method of any one of the clauses herein, wherein causing thediuretic to be provided comprises causing the diuretic to be provided inincrementally-increasing dosages, such that each of the dosages isgreater than the immediately previous dosage.

55. The method of any one of the clauses herein, wherein causing thediuretic to be provided comprises causing the diuretic to be provided inrecurring and increasing dosages, such that the dosage rate is doubledin a time period no more than 20 minutes, 15 minutes, or 10 minutes.

56. The method of any one of the clauses herein, wherein causing thediuretic to be provided comprises causing the dosage rate of thediuretic to increase exponentially.

57. The method of any one of the clauses herein, wherein causing thediuretic to be provided comprises causing the diuretic to be provided incontinuously increasing dosages until at least one of a predeterminedtime period elapses or a threshold urine rate is exceeded.

58. The method of any one of the clauses herein, wherein causing thediuretic to be provided comprises iteratively increasing the dosage ratesuch that the diuretic rate or amount provided to the patient increasesby at least 50%, 100%, or 150%, relative to a previous dosage rate,after a set period of time, the set period of time being no more than 15minutes, 20 minutes, or 30 minutes.

59. The method of any one of the previous clauses, wherein causing thediuretic to be provided to the patient comprises increasing the dosagerate of the diuretic such that the urine output rate is above apredetermined threshold, and wherein adjusting the dosage rate comprisesdecreasing the dosage rate such that a value of the decreased dosagerate is a percentage of a value of a total amount of the diureticprovided to the patient.

60. The method of any one of the previous clauses, wherein causing thediuretic to be provided comprises causing the diuretic to be providedsuch that the urine output rate is above a predetermined threshold, themethod further comprising:

-   -   after causing the diuretic to be provided, determining that the        urine output rate is less than a predetermined threshold; and    -   requesting confirmation from a user or the patient to increase        the diuretic rate.

61. The method of clause 60, further comprising:

-   -   receiving confirmation from the user or the patient to increase        the diuretic rate; and    -   only after receiving the confirmation, increasing the dosage        rate.

62. The method of clause 61, wherein increasing the dosage ratecomprising increasing the dosage rate until the urine output rate risesabove the predetermined threshold.

63. The method of any one of the previous clauses, wherein causing thediuretic to be provided comprises causing the diuretic to be providedsuch that the urine output rate is above a predetermined threshold, themethod further comprising:

-   -   after causing the diuretic to be provided, determining that        average urine output rate over a period of time is less than a        desired threshold, the period of time being at least one hour        and the desired threshold being at least 300 ml/hr; and    -   increasing the dosage rate at least until the urine output rate        is greater than the predetermined threshold.

64. The method of any one of the clauses herein, wherein causing thehydration fluid to be provided to the patient at the hydration ratecomprises causing the hydration rate to be provided such that thehydration rate substantially matches the urine output rate at leastuntil a first amount of hydration fluid is infused, the first amountbeing at least 200 ml or 250 ml.

65. The method of any one of the clauses herein, wherein causing thehydration fluid to be provided to the patient at the hydration ratecomprises causing the hydration rate to be provided such that thehydration rate substantially matches the urine output rate for at leastan initial infusion time, the initial infusion time being 60 minutes.

66. The method of any one of the clauses herein, wherein adjusting atleast one of the dosage rate of the diuretic or the hydration rate ofthe hydration fluid comprises increasing the dosage rate of the diureticand increasing the hydration rate of the hydration fluid, whereinincreasing the hydration rate comprises setting the hydration rate ofthe hydration fluid based on the urine output rate, such that—

-   -   if the urine output rate is below a first threshold, the        hydration rate is set to zero or less than 20 ml/hr; and    -   if the urine output rate is between a second threshold and the        first threshold, the hydration rate is set to 75%-125% of the        urine output rate between the second threshold and the first        threshold.

67. The method of any one of the clauses herein, wherein adjusting atleast one of the dosage rate of the diuretic or the hydration rate ofthe hydration fluid comprises increasing the dosage rate of the diureticand increasing the hydration rate of the hydration fluid, whereinincreasing the hydration rate comprises setting the hydration rate ofthe hydration fluid based on the urine output rate, such that—

-   -   if the urine output rate is below a first threshold, the        hydration rate is set to zero or less than 20 ml/hr;    -   if the urine output rate is between a second threshold and the        first threshold, the hydration rate is set to a first rate equal        to 100% or 75%-125% of the urine output rate between the second        threshold and the first threshold; and    -   if the urine output rate is between a third threshold and the        second threshold, the hydration rate is set to a sum of the (i)        first rate and (ii) 50% or 25% to 75% of the urine output rate        between the third threshold and the second threshold.

68. The method of any one of the clauses herein, wherein adjusting atleast one of the dosage rate of the diuretic or the hydration rate ofthe hydration fluid comprises increasing the dosage rate of the diureticand increasing the hydration rate of the hydration fluid, whereinincreasing the hydration rate comprises setting the hydration rate ofthe hydration fluid based on the urine output rate, such that—

-   -   if the urine output rate is below a first threshold, the        hydration rate is set to zero or less than 20 ml/hr;    -   if the urine output rate is between a second threshold and the        first threshold, the hydration rate is set to a first rate equal        to 100% or 75%-125% of the urine output rate between the second        threshold and the first threshold;    -   if the urine output rate is between a third threshold and the        second threshold, the hydration rate is set to a sum of the (i)        first rate and (ii) a second rate equal to 50% or 25% to 75% of        the urine output rate between the third threshold and the second        threshold; and    -   if the urine output rate is above the third threshold, the        hydration rate is set to a sum of the first rate and the second        rate.

69. The method of any one of the clauses herein, wherein the firstthreshold is no more than 100 ml/hour, 125 ml/hour, 150 ml/hour, 175ml/hour, 200 ml/hour, 225 ml/hour, or 250 ml/hour.

70. The method of any one of the clauses herein, wherein the secondthreshold is no more than 300 ml/hour, 325 ml/hour, 350 ml/hour, 375ml/hour, 400 ml/hour, 425 ml/hour, or 450 ml/hour.

71. The method of any one of the clauses herein, wherein the thirdthreshold is no more than 800 ml/hour, 850 ml/hour, 900 ml/hour, 950ml/hour, 1000 ml/hour, 1025 ml/hour, or 1050 ml/hour.

72. The method of any one of the clauses herein, further comprising, ifthe urine output rate is above a urine output threshold for apredetermined period of time, decreasing the dosage rate of the diureticbased on a down-titration algorithm, the urine output threshold being atleast 500 ml/hour, 525 ml/hour, 550 ml/hour, 1000 ml/hour, 1025 ml/hour,or 1050 ml/hour, the predetermined period of time being at least 2hours, 3 hours, or 4 hours.

73. The method of any one of the clauses herein, further comprising, ifthe urine output rate is above a urine output threshold for apredetermined period of time, decreasing the dosage rate of the diureticby a percentage, the percentage being at least 10%, 25%, or 40%, theurine output threshold being at least 500 ml/hour, 525 ml/hour, 550ml/hour, 1000 ml/hour, 1025 ml/hour, or 1050 ml/hour, the predeterminedperiod of time being at least 2 hours, 3 hours, or 4 hours.

74. The method of any one of clauses 72 or 73, wherein decreasing thedosage rate comprises decreasing the dosage rate of the diuretic untilthe urine output rate is equal to or less than a down-titrationthreshold, the down-titration threshold being at least 50 ml, 100 ml,150 ml, or 200 ml less than the urine output threshold.

75. The method of any one of the clauses herein, wherein adjusting atleast one of the dosage rate comprises decreasing the dosage rate of thediuretic based on a down-titration algorithm if any one or two or all ofa set of conditions is met, the set of conditions including—

-   -   the urine output rate is above a predetermined rate for a        predetermined period of time, the predetermined rate being at        least 500 ml/hour, 750 ml/hour, or 1000 ml/hour, the        predetermined period of time being at least 1 hour, 2 hours, or        3 hours;    -   a rate of change in the urine output rate is above a        predetermined rate for a predetermined period of time, the        predetermined rate being at least 30 ml/hour², 40 ml/hour², or        50 ml/hour², the predetermined period of time being of at least        1 hour, 2 hours, or 3 hours; and    -   the dosage rate of the diuretic is above a predetermined rate,        the predetermined rate being at least 5 mg/hour, 10 mg/hour or        15 mg/hour.

76. The method of any one of the previous clauses, wherein an averagenet fluid loss rate from the patient is at least 50 ml/hour, 75 ml/hour,100 ml/hour, 125 ml/hour, 150 ml/hour, 175 ml/hour, or 200 ml/hour.

77. The method of any one of the previous clauses, wherein an averagenet fluid loss amount from the patient over a day is at least 3 L, 4 L,or 5 L.

78. The method of any one of the previous clauses, further comprising:

-   -   after causing the diuretic to be provided, determining that the        urine output rate is less than a desired threshold; and    -   after determining that the urine output rate is less than the        desired threshold, determining whether the blood pressure of the        patient is below a first predetermined threshold and/or the        electrolyte level of the patient is below a second predetermined        threshold.

79. The method of any one of the previous clauses, wherein the diureticis a first diuretic, the method further comprising:

-   -   after causing the first diuretic to be provided, determining        that the urine output rate is less than a desired threshold; and    -   causing a second diuretic, different than the first diuretic, to        be provided to the patient.

80. The method of any one of the previous clauses, wherein obtaining theurine output rate comprises determining urine output based on at leastone of an optical sensor, a ultrasound sensor, or thermistor.

81. The method of any one of the previous clauses, wherein adjusting atleast one of the dosage rate of the diuretic or the hydration rate ofthe hydration fluid is based on a conductivity, potassium concentration,and/or magnesium concentration of urine from the patient.

82. The method of any one of the clauses herein, wherein causing thehydration fluid to be provided to the patient at the hydration ratecauses a urine salt concentration of the patient to increase, andwherein adjusting at least one of the dosage rate or the diuretic or thehydration rate of the hydration fluid causes the urine saltconcentration of the patient to decrease.

83. The method of any one of the clauses herein, wherein causing thehydration fluid to be provided to the patient at the hydration ratecauses a salt concentration of the patient to increase, and whereinadjusting at least one of the dosage rate or the diuretic or thehydration rate of the hydration fluid causes the salt concentration ofthe patient to decrease.

84. The method of any one of the clauses herein, further comprisingdetermining whether the patient is diuretic resistant.

85. A method for providing fluid therapy, the method comprising:

-   -   obtaining a urine output rate from a patient;    -   causing a diuretic to be provided to the patient at a dosage        rate such that the urine output rate is above a predetermined        threshold;    -   causing a hydration fluid to be provided to the patient at a        hydration rate no more than the urine output;    -   determining whether any one of a predetermined set of conditions        is met; and    -   if at least one of the set of conditions is met, decreasing the        dosage rate of the diuretic by a predetermined amount.

86. The method of any one of the clauses herein, wherein thepredetermined amount is at least 15%, 20%, or 25%, or between 10-40%.

87. The method of any one of the clauses herein, wherein decreasing thedosage rate of the diuretic comprises decreasing the dosage rate of thediuretic by the predetermined amount for a predetermined period of timeof at least 1 hour, 2 hours, or 3 hours.

88. The method of any one of the clauses herein, further comprising,after decreasing the dosage rate of the diuretic, setting the dosagerate based on an algorithm.

89. The method of any one of the clauses herein, wherein determiningwhether any one of predetermined set of condition is met includesdetermining whether the urine output rate is above a predetermined ratefor a predetermined period of time, the predetermined rate being atleast 500 ml/hour, 750 ml/hour, 1000 ml/hour, the predetermined periodof time being of at least 1 hour, 2 hours, or 3 hours.

90. The method of any one of the clauses herein, wherein determiningwhether any one of predetermined set of condition is met includesdetermining whether a rate of change in the urine output rate is above apredetermined rate for a predetermined period of time, the predeterminedrate being at least 30 ml/hour², 40 ml/hour², or 50 ml/hour², thepredetermined period of time being of at least 1 hour, 2 hours, or 3hours.

91. The method of any one of the clauses herein, wherein determiningwhether any one of a predetermined set of condition is met includesdetermining whether the dosage rate of the diuretic is above apredetermined rate, the predetermined rate being at least 5 mg/hour, 10mg/hour or 15 mg/hour.

92. Tangible, non-transitory computer-readable media having instructionsthat, when executed by one or more processors, causes a computing deviceto perform operations comprising the method of any one of the clausesherein.

93. A fluid therapy system, comprising:

-   -   a urine measurement device configured to measure urine output        from a patient;    -   a pump configured to be fluidly coupled to a source of diuretic        and provide the diuretic to the patient;    -   one or more processors; and    -   tangible, non-transitory computer-readable media having        instructions that, when executed by the one or more processors,        cause the fluid therapy system to perform operations comprising—        -   obtaining a urine output rate from the urine measurement            device; and        -   causing the diuretic to be provided, via the pump, to the            patient at a dosage rate, such that a dosage volume is            increased over a period of time of no more than 120 minutes,            wherein an end of the period of time is based at least in            part on the urine output rate being above a predetermined            threshold.

94. The fluid therapy system of any one of the clauses herein, theoperations further comprising, after causing the diuretic to beprovided, setting the dosage rate of the diuretic to be a predeterminedpercentage of a current dosage rate.

95. The fluid therapy system of any one of the clauses herein, theoperations further comprising:

-   -   determining that the urine output rate is above a predetermined        threshold; and    -   setting the dosage rate of the diuretic to be a predetermined        percentage of a total amount of the diuretic delivered at the        time of determining the urine output rate is above the        predetermined threshold.

96. The fluid therapy system of any one of the clauses herein, theoperations further comprising:

-   -   determining that an average urine output rate measured over a        preset time period is above a predetermined threshold; and    -   in response to the determination, decreasing the dosage rate of        the diuretic by a predetermined percentage.

97. The fluid therapy system of any one of the clauses herein, theoperations further comprising:

-   -   determining that one or more of the following set of conditions        exists:        -   (i) an average urine output rate measured over a first            preset time period is above a first predetermined threshold;        -   (ii) the urine output rate measured over a second preset            time period is increasing at a rate above a predetermined            rate of increase;        -   (iii) the dosage rate is above a second predetermined            threshold; and    -   in response to determining that one or more of the set of        conditions exists, decreasing the dosage rate of the diuretic by        a predetermined percentage.

98. The fluid therapy system of any one of the clauses herein, whereinthe first predetermined threshold is at least 500 mL/hour, thepredetermined rate of increase is at least 30 mL/hour², and the secondpredetermined threshold is at least 5 mg/hour.

99. The fluid therapy system of any one of the clauses herein, whereinthe diuretic is provided such that the dosage rate increases by at least200% over the period of time.

100. The fluid therapy system of any one of the clauses herein, whereincausing the diuretic to be provided comprises iteratively increasing thedosage rate in an exponential manner.

101. The fluid therapy system of any one of the clauses herein, theoperations further comprising:

-   -   determining that an average urine output rate measured over a        preset time period is below a predetermined threshold; and    -   in response to the determination, iteratively increasing the        dosage rate of the diuretic in an exponential manner.

102. The fluid therapy system of any one of the clauses herein, whereinthe pump is a first pump, the system further comprising a second pumpconfigured to be operably coupled to a source of hydration fluid andprovide the hydration fluid to the patient, the operations furthercomprising causing the hydration fluid to be provided, via the secondpump, to the patient at a hydration rate no more than the urine outputrate.

103. The fluid therapy system of any one of the clauses herein, whereinthe hydration fluid is provided to the patient such that the hydrationrate substantially matches or is within a predetermined percentage ofthe urine output rate until at least one of (i) a predetermined periodof time has elapsed or (ii) a predetermined amount of hydration fluid isinfused.

104. The fluid therapy system of any one of the clauses herein, whereinthe hydration rate is based on the urine output rate, such that—

-   -   if the urine output rate is below a first threshold, the        hydration rate is set to a first rate; and    -   if the urine output rate is above the first threshold, the        hydrate rate is set to a second rate equal to a sum of the first        rate and a predetermined percentage of the urine output rate        above the first threshold.

105. The fluid therapy system of any one of the clauses herein, whereinthe first threshold is no more than 200 mL/hour, the second threshold isno more than 450 mL/hour, and the predetermined percentage is within arange of 25-75%.

106. The fluid therapy system of any one of the clauses herein, whereinthe hydration rate is set such that a difference between the hydrationrate and the urine output rate increases with as the urine output rateincreases, thereby inducing net fluid loss from the patient.

107. The fluid therapy system of any one of the clauses herein, whereinthe net fluid loss is at least 200 mL/hour.

108. A console for providing fluid therapy to a patient, the consolecomprising:

-   -   a controller having one or more processors and in communication        with—        -   a urine measurement device configured to measure urine            output from a patient;        -   a first pump configured to provide a diuretic to the            patient;        -   a second pump configured to provide a hydration fluid to the            patient; and    -   tangible, non-transitory computer-readable media having        instructions that, when executed by the one or more processors,        cause the fluid therapy system to perform operations comprising—        -   obtaining a urine output rate from the urine measurement            device;        -   causing the diuretic to be provided, via the first pump, to            the patient at a dosage rate, such that a dosage volume is            increased over a period of time; and        -   causing the hydration fluid to be provided, via the second            pump, to the patient at a hydration rate no more than the            urine output rate, thereby promoting a net fluid loss from            the patient.

109. The console of any one of the clauses herein, the operationsfurther comprising, after causing the diuretic to be provided, settingthe dosage rate of the diuretic to be a predetermined percentage of acurrent dosage rate.

110. The console of any one of the clauses herein, the operationsfurther comprising:

-   -   determining that an average urine output rate measured over a        preset time period is above a predetermined threshold; and    -   in response to the determination, decreasing the dosage rate of        the diuretic by a predetermined percentage.

111. The console of any one of the clauses herein, the operationsfurther comprising:

-   -   determining that an average urine output rate measured over a        preset time period is below a predetermined threshold; and    -   in response to the determination, increasing the dosage rate of        the diuretic.

112. The console of any one of the clauses herein, wherein the hydrationfluid is provided to the patient such that the hydration ratesubstantially matches or is within a predetermined percentage of theurine output rate until at least one of (i) a predetermined period oftime has elapsed or (ii) a predetermined amount of hydration fluid isinfused.

113. The console of any one of the clauses herein, wherein the hydrationrate is set such that a difference between the hydration rate and theurine output rate increases with as the urine output rate increases,thereby inducing net fluid loss from the patient.

114. The console of any one of the clauses herein, wherein the hydrationrate is based on the urine output rate, such that—

-   -   if the urine output rate is below a first threshold, the        hydration rate is set to a first rate; and    -   if the urine output rate is above the first threshold, the        hydrate rate is set to a second rate equal to a sum of the first        rate and a predetermined percentage of the urine output rate        above the first threshold.

115. The console of any one of the clauses herein, wherein causing thediuretic to be provided comprises causing the diuretic to be providedsuch that the dosage rate is iteratively increased in an exponentialmanner.

116. A fluid therapy method for promoting net fluid loss from a patient,the method comprising:

-   -   obtaining a urine output rate from a patient;    -   causing a diuretic to be provided to the patient at a dosage        rate, wherein the dosage rate is increased over a period of time        such that the urine output rate increases to be above a        predetermined threshold within the period of time;    -   after the urine output rate increases to be above the        predetermined threshold, setting the dosage rate of the diuretic        to be a predetermined percentage of the current dosage rate; and    -   causing a hydration fluid to be provided to the patient at a        hydration rate.

117. The method of any one of the clauses herein, wherein setting thedosage rate of the diuretic comprises setting the dosage rate of thediuretic to be a predetermined percentage of a total amount of thediuretic delivered to the patient.

118. The method of any one of the clauses herein, wherein causing thediuretic to be provided comprises causing the diuretic to be providedsuch that the dosage rate is iteratively increased in an exponentialmanner.

119. The method of any one of the clauses herein, wherein the dosagerate is iteratively increased in the exponential manner for no more than60 minutes.

120. The method of any one of the clauses herein, further comprising:

-   -   determining that an average urine output rate measured over a        preset time period is below a predetermined threshold; and    -   in response to the determination, iteratively increasing the        dosage rate of the diuretic in an exponential manner.

121. The method of any one of the clauses herein, wherein the hydrationfluid is provided to the patient such that the hydration ratesubstantially matches or is within a predetermined percentage of theurine output rate until at least one of (i) a predetermined period oftime has elapsed or (ii) a predetermined amount of hydration fluid isinfused.

122. The method of any one of the clauses herein, wherein the hydrationrate is based on the urine output rate, such that—

-   -   if the urine output rate is below a first threshold, the        hydration rate is set to a first rate; and    -   if the urine output rate is above the first threshold, the        hydrate rate is set to a second rate equal to a sum of the first        rate and a predetermined percentage of the urine output rate        above the first threshold.

123. The method of any one of the clauses herein, wherein the hydrationrate is set such that a difference between the hydration rate and theurine output rate increases with as the urine output rate increases,thereby inducing net fluid loss from the patient.

I/We claim:
 1. A fluid therapy system comprising: one or moreprocessors; and tangible, non-transitory computer-readable media havinginstructions that, when executed by the one or more processors, causethe fluid therapy system to perform operations comprising— receiving afirst indication that urine output of a patient is at or above a firsturine output threshold and below a second urine output threshold,wherein the second urine output threshold is above the first urineoutput threshold; after receiving the first indication, causinghydration fluid to be infused to the patient at a first hydration fluidrate, wherein the first hydration fluid rate is limited to a firstpredetermined rate while the urine output is below the second urineoutput threshold; receiving a second indication that the urine output isat or above the second urine output threshold; and after receiving thesecond indication, causing the hydration fluid to be infused at a secondhydration fluid rate at or above the first hydration fluid rate, whereinthe second hydration fluid rate is less than the urine output.
 2. Thefluid therapy system of claim 1, wherein: when the urine output of thepatient is between the first urine output threshold and the second urineoutput threshold, the urine output is greater than the first hydrationfluid rate by a first amount, when the urine output of the patient isbetween the second urine output threshold and a third urine outputthreshold greater than the second urine output threshold, the urineoutput is greater than the second hydration fluid rate by a secondamount, and the second amount is greater than the first amount.
 3. Thefluid therapy system of claim 1, wherein causing the hydration fluid tobe infused at the first hydration fluid rate is configured to correspondto a first sodium level of the patient, and wherein causing thehydration fluid to be infused at the second hydration fluid rate isconfigured to correspond to a second sodium level of the patient lessthan the first sodium level, wherein the first and second sodium levelsare below a predetermined sodium threshold level.
 4. The fluid therapysystem of claim 1, wherein causing the hydration fluid to be infused tothe patient at the first hydration fluid rate and causing the hydrationfluid to be infused to the patient at the second hydration fluid rateare each configured to inhibit an increase in sodium levels of thepatient.
 5. The fluid therapy system of claim 1, wherein the operationsfurther comprise: receiving a third indication that the urine output isat or above a third urine output threshold, wherein the third urineoutput threshold is above the second urine output threshold; and afterreceiving the third indication, causing the hydration fluid to beinfused at a third hydration fluid rate at or above the second hydrationfluid rate.
 6. The fluid therapy system of claim 5, wherein theoperations further comprise: receiving a fourth indication that theurine output is at or above a fourth urine output threshold, wherein thefourth urine output threshold is above the third urine output threshold;and after receiving the fourth indication, causing the hydration fluidto be infused at a fourth hydration fluid rate at or above the thirdhydration fluid rate.
 7. The fluid therapy system of claim 5, whereinthe first urine output threshold is at least 175 milliliters/hour, thesecond urine output threshold is at least 375 milliliters/hour, and thethird urine output threshold is at least 975 milliliters/hour.
 8. Thefluid therapy system of claim 5, wherein: causing the hydration fluid tobe infused at the first hydration fluid rate is configured to correspondto a first net fluid balance of the patient, causing the hydration fluidto be infused at the second hydration fluid rate is configured tocorrespond to a second net fluid balance of the patient less than thefirst net fluid balance, and causing the hydration fluid to be infusedat the third hydration fluid rate is configured to correspond to a thirdnet fluid balance of the patient less than the second net fluid balance.9. The fluid therapy system of claim 1, further comprising a first pumpconfigured to provide the hydration fluid to the patient and a secondpump configured to provide a diuretic to the patient.
 10. The fluidtherapy system of claim 1, wherein the operations further comprise, whenthe urine output is below the first urine output threshold, not causingthe hydration fluid to be infused.
 11. A fluid therapy systemcomprising: a urine measurement device configured to measure urineoutput from a patient; a pump configured to provide a hydration fluid tothe patient; one or more processors; and tangible, non-transitorycomputer-readable media having instructions that, when executed by theone or more processors, cause the fluid therapy system to performoperations comprising— obtaining a urine output rate via the urinemeasurement device; when the urine output is within a first urine outputrange, causing the hydration fluid to be infused via the pump at a firsthydration fluid rate lower than the urine output; and when the urineoutput is within a second urine output range, causing the hydrationfluid to be infused via the pump at a second hydration fluid rate lowerthan the urine output and higher than the first hydration fluid rate.12. The fluid therapy system of claim 11, wherein causing the hydrationfluid to be infused via at the first hydration fluid rate is configuredto correspond to a first sodium level of the patient, and whereincausing the hydration fluid to be infused at the second hydration fluidrate is configured to correspond to a second sodium level of the patientless than the first sodium level.
 13. The fluid therapy system of claim11, wherein the second urine output range is higher than the first urineoutput range such that an upper end of the second urine output range ishigher than an upper end of the first urine output range.
 14. The fluidtherapy system of claim 11, wherein the operations further comprise,when the urine output is within a third urine output range, causing thehydration fluid to be infused via the pump at a third hydration fluidrate higher than the second hydration fluid rate.
 15. The fluid therapysystem of claim 14, wherein the first urine output threshold is at least175 milliliters/hour, the second urine output threshold is at least 375milliliters/hour, and the third urine output threshold is at least 975milliliters/hour.
 16. The fluid therapy system of claim 15, wherein:causing the hydration fluid to be infused at the first hydration fluidrate is configured to correspond to a first net fluid balance, causingthe hydration fluid to be infused at the second hydration fluid rate isconfigured to correspond to a second net fluid balance less than thefirst net fluid balance; and causing the hydration fluid to be infusedat the third hydration fluid rate is configured to correspond to a thirdnet fluid balance less than the second net fluid balance.
 17. The fluidtherapy system of claim 11, wherein the first urine output range isconfigured to correspond to a minimum urine output of no less than 175milliliters/hour and a maximum urine output of no more than 375milliliters/hour.
 18. The fluid therapy system of claim 11, wherein thefirst urine output range is configured to correspond to a minimum urineoutput rate of 175 milliliters/hour and the second urine outputthreshold is at least 375 milliliters/hour.
 19. The fluid therapy systemof claim 11, wherein: when the urine output is within the first urineoutput range, the first hydration fluid rate is directly correlated tothe urine output, such that the first hydration fluid rate increases asthe urine output increases based on a first coefficient; and when theurine output is within the second urine output range, the secondhydration fluid rate is directly correlated to the urine output, suchthat the second hydration fluid rate increases as the urine outputincreases based on a second coefficient, wherein the second coefficientis lower than the first coefficient.
 20. The fluid therapy system ofclaim 11, wherein: when the urine output is within the first urineoutput range, the first hydration fluid rate is directly correlated tothe urine output, such that the first hydration fluid rate increases asthe urine output increases; and when the urine output is within thesecond urine output range, the second hydration fluid rate does notincrease as the urine output rate increases.
 21. A fluid therapy systemcomprising: one or more processors; and tangible, non-transitorycomputer-readable media having instructions that, when executed by theone or more processors, cause the fluid therapy system to performoperations comprising— obtaining a urine output of a patient; andcausing a hydration fluid to be infused to the patient at a hydrationfluid rate lower than the urine output, wherein, as the urine output ofthe patient increases, an absolute value of the difference between theurine output and the hydration fluid rate increases.
 22. The fluidtherapy system of claim 21, wherein the hydration fluid rate is directlycorrelated to the urine output such that the hydration fluid rateincreases as the urine output increases.
 23. The fluid therapy system ofclaim 21, wherein: when the urine output of the patient is in a firsturine output range, the hydration fluid is infused at a first hydrationfluid rate, and when the urine output of the patient is in a secondurine output range higher than the first urine output range, thehydration fluid is infused at a second hydration fluid rate higher thefirst hydration fluid rate.
 24. The fluid therapy system of claim 23,wherein the hydration fluid rate is directly correlated to the urineoutput, and wherein: when the urine output is within the first urineoutput range, the first hydration fluid rate is directly correlated tothe urine output, such that the first hydration fluid rate increases asthe urine output increases based on a first coefficient, and when theurine output is within the second urine output range, the secondhydration fluid rate is directly correlated to the urine output, suchthat the second hydration fluid rate increases as the urine outputincreases based on a second coefficient, wherein the second coefficientis lower than the first coefficient.
 25. The fluid therapy system ofclaim 23, wherein the first hydration fluid rate is limited to a firstpredetermined rate while the urine output is within the first urineoutput range and the second hydration fluid rate is limited to a secondpredetermined rate while the urine output is within the second urineoutput range.